RRM Glossary: A Detailed Reference to Restorative Reproductive Medicine

Overview

This glossary defines the clinical terms, methods, and conditions used in restorative reproductive medicine (RRM), drawn from peer-reviewed research and active clinical practice, and maintained by RRM Academy for patients and clinicians.

Restorative Reproductive Medicine (RRM) is a specialized field of medicine that focuses on identifying the underlying health conditions contributing to reproductive dysfunction, then treating them to restore the natural functions of the reproductive system. Unlike conventional approaches that suppress or bypass normal physiology, RRM seeks to cooperate with the body: diagnosing, understanding, and addressing underlying health concerns to improve overall wellness and restore reproductive abilities. This glossary provides a thorough, well-cited reference for the terminology, methods, conditions, and procedures encountered within the RRM framework.¹

Part I: Core RRM Principles

Restorative Reproductive Medicine (RRM)

A specialized medical approach focused on identifying and correcting underlying causes of infertility, recurrent miscarriage, gynecologic pain, abnormal bleeding, and other reproductive dysfunctions, aiming to restore natural fertility and physiological function rather than bypass or suppress it. RRM includes lifestyle changes, patient education in fertility cycle awareness, medical treatments supporting ovulation and implantation, and surgery to remove pathologic tissue and restore normal anatomy. The goal is improved health, which leads to the natural ability to conceive.²³⁴¹

Root Cause Diagnosis

The foundational RRM principle that reproductive health problems (including infertility, abnormal bleeding, and chronic pain) are symptoms of identifiable underlying causes, not final diagnoses in themselves. Underlying causes may include hormonal imbalances, structural abnormalities (e.g., tubal blockage, uterine defects), inflammatory conditions, autoimmune disorders, metabolic dysfunction, or iatrogenic factors such as C-section scar defects or prior surgical complications. RRM does not accept "unexplained infertility" as a final answer, but continues deeper investigation to find treatable hidden causes.³⁴

Restorative (as a Principle)

Pertaining to the goal of repairing, healing, and optimizing the natural function of the reproductive system. The restorative approach contrasts with suppressive therapies (e.g., hormonal contraception used to mask cycle symptoms) and bypass therapies (e.g., IVF circumventing tubal disease). It also encompasses removal of problematic devices and reversal of prior procedures such as tubal ligation to restore health or fertility potential.¹

Natural Fertility

The inherent biological capacity for reproduction through in vivo (in the body) conception, without gamete removal or external fertilization. RRM aims to restore or optimize natural fertility through corrective medical and surgical interventions, including procedures like tubal reversal.¹

Body Literacy

An individual's informed understanding of their own biological signs and reproductive cycle, typically developed through systematic fertility charting. Body literacy empowers patients to recognize abnormalities early, time intercourse and diagnostics appropriately, and participate actively in their own care.¹

Comprehensive Evaluation

A thorough RRM assessment designed to identify underlying conditions. Typically includes detailed cycle charting (using the Creighton Model or other FABMs), timed hormonal blood tests, ultrasound series (including saline infusion sonohysterogram for structural assessment), hysterosalpingogram (HSG), semen analysis, and targeted testing for endocrine, immune, clotting, or genetic factors. Diagnostic and/or operative laparoscopy and hysteroscopy are employed when indicated, essential for definitive diagnosis of endometriosis, pelvic adhesions, chronic endometritis, and isthmoceles.³

Personalized Treatment

The practice of tailoring medical and/or surgical interventions to the specific underlying conditions identified during evaluation, incorporating patient goals (e.g., desire for future fertility influences the choice of isthmocele repair method). Treatment plans may include targeted hormonal therapy, ovulation induction, luteal phase support, nutritional protocols, lifestyle modifications, and specialized surgery.¹

Holistic Approach

Consideration of the whole person and the interplay of bodily systems (endocrine, immune, metabolic, inflammatory, musculoskeletal) and their collective impact on reproductive health. RRM addresses genetics, lifestyle, prior interventions, and overall systemic wellness alongside specific pelvic pathology.¹

Reproductive Health Optimization

The overarching RRM goal of improving the overall health and function of the reproductive system: encompassing fertility, cycle regularity, absence of pain or abnormal bleeding, hormonal balance, and long-term gynecologic wellness. Achieving pregnancy is a result of restored health, not merely the isolated procedural endpoint.¹

Corrective vs. Bypass/Suppressive

A key RRM conceptual distinction. RRM aims to correct underlying anatomical, hormonal, or immunological problems (e.g., surgical repair of fallopian tubes, isthmocele reconstruction, adhesion excision), whereas bypass therapies circumvent infertility problems (IVF bypasses tubal blockage), suppressive therapies mask symptoms (hormonal contraception for endometriosis pain), and hysterectomy removes the affected organ entirely.¹

Part II: Fertility Awareness and Charting Methods

Fertility Awareness-Based Methods (FABMs)

An umbrella term for scientific methods used to monitor and interpret biological signs of fertility (biomarkers) throughout the menstrual cycle. FABMs can be used for health monitoring, timing diagnostics and treatments in RRM, and achieving or avoiding pregnancy. A 2025 systematic review of 20,339 participants from 16 studies found that FABMs, when used correctly, were associated with a success rate of over 90% for both contraception and conception purposes. FABMs encourage partner involvement, improve communication, and enhance body literacy by tracking female biomarkers to determine fertility status, and can also help diagnose ovulation-related disorders such as PCOS and endometriosis. Note: The Creighton Model FertilityCare System is specifically classified as an NFP method by its developers and is distinct from the FABM umbrella.⁵⁶

Fertility Charting

The systematic daily recording of fertility biomarkers according to a specific standardized method, such as the Creighton Model or another FABM. Chart data function analogously to an ECG for the reproductive system, revealing hormonal patterns, potential abnormalities, and optimal windows for diagnostics, treatment timing, and intercourse. Changes in charting patterns serve as a form of biofeedback to assess treatment efficacy.¹

Biomarkers (Fertility)

Observable biological signs that change predictably across the menstrual cycle and indicate reproductive status. Primary biomarkers directly reflect hormonal activity: the cervical mucus pattern (appearance, sensation, elasticity) shifts with rising estrogen, basal body temperature (BBT) rises 0.2 to 0.5 degrees C after progesterone release, and hormone levels (LH, FSH, estradiol, progesterone) are measurable via blood tests or urine metabolites. Secondary biomarkers include cycle length patterns, bleeding characteristics, cervical position and texture, mittelschmerz (mid-cycle pelvic pain), and breast tenderness. In RRM, biomarkers function clinically rather than merely observationally: charted patterns identify the fertile window, confirm ovulation, flag luteal phase deficiency, and time cycle-phase-specific diagnostics and treatments.¹

Natural Family Planning (NFP)

Methods used to achieve or avoid pregnancy based on identifying the fertile window through observation of biological signs. The Creighton Model FertilityCare System is a specific, standardized NFP method foundational to NaProTECHNOLOGY. NFP and FABM are sometimes used interchangeably in clinical literature, though they are not identical categories.

Creighton Model FertilityCare System (CrMS)

A standardized, prospective method of Natural Family Planning (NFP) focused on detailed observation and classification of cervical mucus patterns and other biological markers, developed at the Pope Paul VI Institute by Dr. Thomas Hilgers. The CrMS is distinct from the broader FABM category. Its developers specifically distinguish it as an NFP method. The CrMS provides precise information for monitoring gynecologic health and fertility and forms the diagnostic foundation for NaProTECHNOLOGY, allowing cycle-phase-specific timing of blood tests and medical treatments. Published effectiveness data show CrMS is up to 98% effective for achieving pregnancy in couples with normal fertility and, in conjunction with NaPro, up to 80% effective for couples experiencing infertility. A prospective cohort study (CEIBA) in 17 CrMS centers across the USA and Canada found the highest 13-cycle pregnancy rate with correct use to conceive was 89.6%, when intercourse was timed to peak-type mucus days.⁷⁸⁹

Peak Day

In mucus-based methods (including the Billings Ovulation Method), the last day of fertile-type cervical mucus (characterized as clear, stretchy, or lubricative) correlating closely with the time of ovulation. Peak Day marks the transition point in the mucus pattern from fertile-type to post-ovulatory. In CrMS, Peak Day identification is critical for timing luteal progesterone support in NaPro Medical protocols.⁸

Billings Ovulation Method

A standardized FABM developed by Australian physicians Drs. John and Evelyn Billings in the 1960s, based entirely on the sensation and appearance of cervical mucus at the vulva to identify the fertile window. The Billings method requires no temperature taking and no instruments, making it globally accessible across cultural and resource settings; it has been studied in field trials supported by the World Health Organization. Users record daily observations according to standardized rules, identifying the "Peak Day" (the last day of fertile-type mucus) and counting subsequent infertile days. Published effectiveness data from large multi-country trials report method-related pregnancy rates of approximately 1% per year when used correctly to avoid pregnancy. Billings is the foundational mucus-based method from which the Creighton Model was later standardized; it shares core mucus methodology with CrMS while remaining a distinct method with its own teaching network.

FEMM (Fertility Education and Medical Management)

An FABM program integrating hormonal science with cycle charting and providing a structured framework for medical management based on cycle data. FEMM incorporates hormone monitoring alongside mucus observations and is used both for family planning and for gynecological health management within RRM.¹

Sympto-Thermal Method (STM)

A cycle charting method combining multiple biomarkers (primarily cervical mucus changes and basal body temperature (BBT) shifts) to identify the fertile window. BBT rises approximately 0.2 to 0.5 degrees C following ovulation due to progesterone secretion from the corpus luteum. STM identifies the pre-ovulatory and post-ovulatory infertile phases using both markers.

Marquette Method

A FABM developed at Marquette University by Dr. Richard Fehring and colleagues that uses the ClearBlue Fertility Monitor to measure urinary estrogen and LH metabolites, producing objective low, high, and peak fertility readings. The monitor-based protocol can be used alone or combined with cervical mucus and basal body temperature observations, depending on user preference. Quantifiable hormone data provides a second independent confirmation of fertility status, which is particularly valuable for women with irregular cycles, postpartum and breastfeeding women, and women in perimenopause, where mucus patterns alone may be harder to interpret. Published effectiveness data from prospective cohort studies report perfect-use pregnancy rates of approximately 2% per year to avoid pregnancy. Marquette is also used clinically through the FACTS (Fertility Appreciation Collaborative to Teach the Science) training program; see Marquette Method Clinical Protocol for the medical-management arm.¹

Basal Body Temperature (BBT)

The body's resting temperature, measured orally or vaginally first thing in the morning after at least three hours of uninterrupted sleep and before any activity, eating, or drinking. BBT rises 0.2 to 0.5 degrees C within one to three days after ovulation due to the thermogenic effect of progesterone released by the corpus luteum; this sustained shift produces a characteristic biphasic pattern on a cycle chart. A thermal shift confirms that ovulation has occurred but cannot predict ovulation in advance. BBT is therefore useful for retrospective ovulation confirmation, luteal phase length measurement, and detection of a short luteal phase (<10 days) or anovulation, but is not reliable as the sole marker for identifying the fertile window. Accuracy depends on consistent timing, adequate sleep, and the absence of confounders (illness, alcohol, disturbed sleep, shift work). BBT is a core component of sympto-thermal methods and a secondary confirmatory marker in several other FABMs.

Mucus Pattern

The characteristic sequence of cervical mucus changes that occurs across the menstrual cycle, observable through sensation and visual inspection. Estrogen stimulates cervical crypts to produce mucus that becomes progressively more fluid, stretchable, and lubricative as ovulation approaches. After ovulation, progesterone causes an abrupt shift to a dry or tacky pattern. The transition from fertile-type to post-ovulatory mucus identifies Peak Day.

Mucus pattern is a primary biomarker in every mucus-based FABM. The Creighton Model FertilityCare System, the Billings Ovulation Method, and FEMM all use standardized descriptors for mucus type, sensation, and appearance. Charted over time, the pattern gives clinicians direct evidence of estrogen activity, ovulation timing, and cervical factor status.

Disrupted mucus patterns are clinically significant. Sparse or absent fertile-type mucus despite confirmed ovulation points toward cervical factor infertility. Prolonged mucus patches outside the expected fertile window can reflect hormonal dysregulation, chronic cervicitis, or medication effects. In RRM practice, mucus pattern data from the chart is not discarded as subjective. It is treated as observable cervical endocrine output.

Research by Billings and colleagues established the physiological basis for mucus charting as a fertility signal.⁷⁴ For couples pursuing fertility restoration, mucus pattern interpretation is often the first diagnostic data point available, well before laboratory panels or imaging.

Part III: Clinical Approaches

NaProTECHNOLOGY (Natural Procreative Technology)

A specific women's health science focused on reproductive and gynecologic health, developed by Dr. Thomas Hilgers at the Pope Paul VI Institute. It utilizes the Creighton Model FertilityCare System for precise cycle monitoring to guide targeted medical (NaPro Medical) and surgical (NaPro Surgery/Advanced Reproductive Surgery) treatments based on identified cycle abnormalities. NaProTECHNOLOGY works cooperatively with the reproductive system and does not employ methods that are inherently suppressive, circumventive, or destructive. In Hilgers (2004), a cohort of 1,045 infertile patients reported cumulative live-birth rates exceeding 60% by 24 months and approximately 70% by 36 months.¹⁰ More recently, Sanchez-Mendez et al. (2025) followed 1,310 couples and reported cumulative live-birth rates of 50% at 24 months and 62.1% at 36 months or longer.¹¹¹² Both figures are comparable to or higher than cumulative live-birth rates achieved after one or more IVF cycles

NaPro Medical

The medical management component of NaProTECHNOLOGY, using timed medications and supplements based on Creighton Model charting data. Treatments are cycle-phase-specific (e.g., luteal progesterone support is timed to the post-peak phase; ovulation induction agents are timed to the follicular phase). Common interventions include targeted hormone therapy (progesterone, estrogen, HCG), ovulation induction (clomiphene, letrozole), thyroid management, and treatment of conditions like hyperprolactinemia or insulin resistance.¹¹¹²

NaPro Surgery / Advanced Reproductive Surgery

The specialized surgical component of NaProTECHNOLOGY, employing meticulous, often minimally invasive techniques to restore anatomy and function or remove problematic conditions. Hallmarks include excision (rather than ablation/fulguration) of endometriosis, meticulous adhesiolysis with anti-adhesion barrier protocols, microsurgical tubal repair and reversal, multi-layer isthmocele reconstruction, and fertility-preserving ovarian surgery. Published results have documented adhesion scores dropping dramatically with the introduction of extensive Gore-Tex barrier use in NaPro surgeries, from a mean score of 33.3 to 6.0 over a decade.¹⁰

Fertilitas Study

One of the largest single-center NaProTECHNOLOGY cohort studies to date, demonstrating a take-home baby (THB) rate of 35.3% overall, rising to 62.1% among patients who remained with the program for the full duration of treatment. The study confirmed NaPro as associated with a notably high THB rate even in patients with unfavorable prognostic factors such as advanced maternal age, prolonged infertility duration, and prior failed ART attempts. Conditions associated with higher THB rates included recurrent pregnancy loss, hormonal/functional disorders, endometriosis, and male factor infertility.¹³¹⁴

FEMM Medical Management

The clinical treatment arm of the FEMM (Fertility Education and Medical Management) program, in which trained medical providers use cycle charting data (cervical mucus observations and urinary LH testing) alongside cycle-timed lab work to diagnose and treat reproductive and hormonal disorders. FEMM Medical Providers follow protocols developed by the Reproductive Health Research Institute (RHRI) under Dr. Pilar Vigil. Treatment categories include PCOS, thyroid dysfunction, luteal phase deficiency, recurrent pregnancy loss, anovulation, and menopausal disorders. FEMM is distinct from NaProTechnology in its charting method (sympto-hormonal rather than Creighton-only), institutional affiliation (RHRI rather than Saint Paul VI Institute), and protocol framework.¹

FEMM Education Levels (Teen, Adult, Medical)

FEMM offers three tiered pathways matched to life stage and clinical need. Teen FEMM introduces adolescent girls to the hormonal and ovulatory basis of the menstrual cycle as a vital sign of overall health, without contraceptive framing. Adult FEMM teaches cycle charting (sympto-hormonal approach with mucus observation and optional urinary LH testing) for use in family planning and health awareness. FEMM Medical Management is the clinical arm in which trained FEMM Medical Providers use charting data alongside cycle-timed lab work to diagnose and treat hormonal and reproductive disorders (see FEMM Medical Management). The three tiers allow FEMM content to meet users at different stages of the reproductive life course with appropriate depth and clinical integration.¹

Reproductive Health Research Institute (RHRI)

The research and training organization behind FEMM's medical management protocols, founded by Dr. Pilar Vigil, a specialist in obstetrics, gynecology, and reproductive endocrinology. RHRI has published peer-reviewed research linking chronic anovulation to long-term health risks including cardiovascular disease and Type 2 diabetes, and has developed clinical protocols for PCOS phenotyping, thyroid-related cycle disruption, and immune evaluation for recurrent pregnancy loss.¹

Sympto-Hormonal Method

A fertility awareness-based method that combines cervical mucus observation with urinary hormone testing (typically LH strips) to track ovulation. FEMM uses a sympto-hormonal approach, distinguishing it from mucus-only methods (Creighton, Billings) and sympto-thermal methods (which add basal body temperature). The addition of objective hormone data provides a second independent confirmation of ovulatory events.¹

NeoFertility

A clinical system developed by Dr. Phil Boyle that builds on NaProTechnology training with expanded diagnostic protocols, particularly in reproductive immunology and androgen evaluation. NeoFertility treats infertility, recurrent miscarriage, and at-risk pregnancy using a structured three-phase process: comprehensive diagnosis (Phase 1), treatment and cycle optimization (Phase 2), and conception timing with confirmed follicle rupture (Phase 3). NeoFertility is method-agnostic: it accepts charting data from any FABM, not only the Creighton Model.¹

ChartNeo

NeoFertility's digital charting platform that integrates patient charting data with the clinical workflow. ChartNeo connects patients, fertility advisors, and clinicians through shared data, enabling remote monitoring and telehealth delivery. Unlike standalone charting apps, ChartNeo is designed as a clinical tool that feeds directly into diagnostic and treatment decisions.

Low-Dose Naltrexone (LDN)

An immune-modifying agent used at 4.5 mg nightly in the NeoFertility protocol for patients with reduced egg reserve, suspected immune-mediated implantation failure, and clinical endorphin deficiency. Originally developed as an opioid antagonist at higher doses, LDN at low doses modulates immune function by temporarily blocking opioid receptors, triggering a compensatory increase in endorphin production. Published data from NeoFertility shows LDN use associated with significant enhancements in endometrial thickness, ovarian responsiveness, progesterone levels, and clinical pregnancy rates.

DHEA (Dehydroepiandrosterone) in RRM

An androgen precursor used in NeoFertility protocols to address hypoandrogenemia, abnormally low androgen levels identified as a contributor to recurrent pregnancy loss and diminished ovarian reserve. DHEA evaluation is part of NeoFertility's expanded diagnostic panel. When indicated, supplementation aims to restore androgen levels that support follicular development and early pregnancy maintenance.

Immune-Modifying Framework

NeoFertility's systematic approach to evaluating and treating immunological factors in infertility and recurrent miscarriage. The framework includes NK cell panels (natural killer cell activity), food antibody testing, chromosomal abnormality screening, blood clotting markers, and chronic endometritis investigation. Treatment may include LDN, intralipid infusions, corticosteroids, and anticoagulation therapy. This represents one of NeoFertility's most significant expansions beyond standard NaProTechnology protocols.

Marquette Method Clinical Protocol

A fertility awareness-based method that uses the ClearBlue Fertility Monitor to measure urinary estrogen and LH levels, providing objective hormone data alongside optional cervical mucus and temperature observations. Developed at Marquette University, the method has been integrated into clinical RRM practice through the FACTS training program. The monitor-based approach appeals to clinicians who want quantifiable hormone data as part of the diagnostic workup. Marquette-trained Medical Consultants use the charting data for cycle-timed diagnostics in a framework similar to NaProTechnology and FEMM.¹

HCG Trigger (Human Chorionic Gonadotropin Trigger)

A single injection of human chorionic gonadotropin (hCG) given during an ovulation induction or monitored cycle to mimic the natural LH surge, triggering final follicular maturation and ovulation. In NaPro Medical and related RRM protocols, hCG triggering is used selectively when cycle-timed monitoring identifies a mature follicle with a delayed or absent endogenous LH surge, or to improve the precision of ovulation timing in combination with ovulation induction agents such as clomiphene or letrozole. Post-ovulatory hCG "boosters" also support corpus luteum function and early luteal progesterone production. Unlike IVF protocols, which use hCG triggering to time oocyte retrieval, RRM protocols use it to support natural intercourse-timed conception within the body.

Part IV: Diagnostic Tools and Techniques

Follicle Maturation Study (Follicle Tracking / Follicular Ultrasound Series)

A series of transvaginal ultrasounds performed across the follicular phase of the menstrual cycle to monitor follicle development, dominant follicle selection, and ovulation. Findings inform diagnosis of luteinized unruptured follicle (LUF) syndrome, ovulatory dysfunction, and are used to time hormonal interventions precisely.

Saline Infusion Sonohysterogram (SIS) / "Bubble Test"

A transvaginal ultrasound performed while infusing sterile saline into the uterine cavity, providing enhanced visualization of the endometrial cavity and uterine walls. SIS is the primary diagnostic tool for uterine isthmocele, enabling measurement of the defect dimensions and residual myometrial thickness. It also detects endometrial polyps, submucosal fibroids, intrauterine adhesions, and uterine septa, and can assess tubal patency.¹⁵¹⁶

Hysterosalpingogram (HSG)

A radiographic procedure in which contrast dye is introduced through the cervix into the uterine cavity and fallopian tubes under fluoroscopic guidance. HSG assesses uterine cavity morphology and tubal patency. It is often the first-line imaging tool for evaluating tubal factor infertility.¹⁷

Selective Salpingography

A specialized variant of HSG in which contrast dye is injected selectively into each fallopian tube individually via a catheter. This allows targeted assessment and, in some cases, simultaneous therapeutic recanalization of proximal tubal blockages.

Hysteroscopy (Diagnostic)

Direct visualization of the uterine cavity and cervical canal using a hysteroscope (a thin, illuminated camera). Considered the gold standard for evaluation and management of intrauterine pathology. Diagnostic hysteroscopy is indicated for evaluation of abnormal uterine bleeding, recurrent miscarriage, repeated implantation failure, and suspected structural abnormalities. In premenopausal women with regular cycles, optimal timing is during the early follicular phase after menstruation.¹⁸¹⁷

Hysteroscopy (Operative)

A therapeutic extension of diagnostic hysteroscopy, used to treat intrauterine pathology identified during visualization. ACOG-recognized indications include removal of endometrial polyps, submucosal leiomyomas (fibroids), uterine septa, intrauterine adhesions (synechiae), retained products, malpositioned IUDs, tubal cannulation, and treatment of isthmoceles. Ambulatory (office-based) hysteroscopy offers comparable outcomes to operating room procedures with reduced cost and avoidance of general anesthesia.¹⁷¹⁸

Laparoscopy (Diagnostic)

Minimally invasive visualization of the pelvic and abdominal organs through small incisions using a laparoscope. In RRM, diagnostic laparoscopy is often the definitive method for diagnosing endometriosis and pelvic adhesions, conditions frequently missed on imaging alone. The Systematic Mapping of the Abdomen and Pelvis (S-MAP) protocol is employed during NaPro diagnostic laparoscopy for comprehensive abdominal and pelvic assessment.

Laparoscopy (Operative)

Minimally invasive surgical treatment performed laparoscopically for conditions including endometriosis (via excision), pelvic adhesions (adhesiolysis), uterine fibroids (myomectomy), ovarian cysts (cystectomy), fallopian tube disease (repair, reversal, neosalpingostomy), isthmocele (laparoscopic excision and multi-layer reconstruction), and PCOS (ovarian wedge resection).¹⁷

Near Contact Laparoscopy

A specialized laparoscopic technique in which the laparoscope is brought into close proximity to tissue to achieve high-magnification visualization. Used in NaPro Surgery for precise identification of subtle endometriosis implants and peritoneal disease that might be missed at standard laparoscopic distance.

S-MAP (Systematic Mapping of the Abdomen and Pelvis)

A methodical, standardized protocol for comprehensive examination of all abdominal and pelvic structures during laparoscopy, ensuring that no area of disease is overlooked. The S-MAP method follows the systematic evaluation sequence described by Dr. Thomas Hilgers in the NaProTECHNOLOGY textbook (Chapter 63); the term "S-MAP" was coined by Dr. Naomi Whittaker. Used in combination with Near-Contact Laparoscopy (NCL), S-MAP evaluates the upper abdomen (diaphragm, gallbladder), lower abdomen (cecum, appendix), and all pelvic structures (anterior and posterior cul-de-sac) in the same reproducible sequence every time. Dr. Whittaker presented a case series at AAGL 2024 demonstrating that NCL/S-MAP led to the incidental diagnosis and curative treatment of four rare cancers during fertility/pain surgeries by a single surgeon over three years.

Semen Analysis

The primary diagnostic test for male factor infertility, evaluating sperm concentration (count), motility, morphology (shape), volume, and other parameters. A normal semen analysis does not exclude male factor, as it does not assess sperm DNA integrity; additional testing (see Sperm DNA Fragmentation Index) may be warranted in cases of unexplained infertility or recurrent miscarriage.

Sperm DNA Fragmentation Index (DFI)

A measure of the proportion of sperm with damaged or fragmented DNA. High SDF is associated with poor reproductive outcomes including reduced natural conception rates, failed IUI, increased miscarriage risk, and impaired embryo development. Standard semen analysis does not assess DNA integrity, making SDF testing an important adjunct in evaluating unexplained infertility, recurrent pregnancy loss, and repeated ART failure. Treatment strategies include lifestyle modification, antioxidant therapy, varicocele repair, and in select cases, testicular sperm retrieval.^19202122

Endometrial Receptivity Analysis (ERA)

A molecular diagnostic test that evaluates gene expression in an endometrial biopsy sample to determine the personalized "window of implantation" (WOI), the period during which the endometrium is most receptive to embryo implantation. The ERA analyzes the expression profile of 236 to 238 genes related to endometrial receptivity status. In approximately 20 to 25% of women with recurrent implantation failure, the WOI is displaced from the standard timing. A study of 3,605 patients found that clinical pregnancy rate and live birth rate improved after personalized embryo transfer guided by ERA results, particularly in recurrent implantation failure patients.²³²⁴²⁵

CD138 (Syndecan-1) Immunohistochemistry

A staining technique used on endometrial biopsy specimens to identify plasma cells, which are pathognomonic (definitively diagnostic) for chronic endometritis. CD138 IHC is more sensitive than routine histology alone for detecting chronic endometritis and is the current standard for diagnosis when chronic endometritis is suspected.²⁶

EMMA / ALICE (Endometrial Microbiome Testing)

Molecular diagnostic tests that analyze the endometrial microbiome from a biopsy sample. EMMA (Endometrial Microbiome Metagenomic Analysis) measures the abundance and composition of endometrial bacteria, including the proportion of Lactobacillus (considered protective) and the presence of dysbiotic organisms. ALICE (Analysis of Infectious Chronic Endometritis) identifies pathogenic bacteria specifically associated with chronic endometritis. EMMA and ALICE are often ordered together with Endometrial Receptivity Analysis (ERA) from a single biopsy as an "EndomeTRIO" panel. Microbiome-targeted probiotic and antibiotic treatments guided by these results have been studied as adjuncts for women with recurrent implantation failure and recurrent pregnancy loss, though evidence quality varies across studies.⁶⁵

PGT-A (Preimplantation Genetic Testing for Aneuploidy)

Preimplantation genetic testing for aneuploidy (PGT-A) is a laboratory test performed on an embryo biopsy during IVF to screen for chromosomal aneuploidy before transfer. Formerly called PGS (preimplantation genetic screening), PGT-A is marketed as a tool to improve IVF success rates by selecting only chromosomally normal (euploid) embryos for transfer. The evidence for routine use in good-prognosis patients does not support the marketing claim. The STAR trial, a multicenter randomized controlled trial in good-prognosis IVF patients, found no significant difference in cumulative live-birth rates between PGT-A selection and morphology-based selection alone (37.0% vs. 35.9%; the difference was not statistically significant).⁵⁹ PGT-A improves per-transfer success rates by removing aneuploid embryos from the transfer queue, but it does not improve cumulative outcomes because it simultaneously reduces the number of embryos available for transfer. An additional concern: embryos classified as mosaic (partially aneuploid) are often excluded from transfer, yet mosaic embryos are capable of producing healthy pregnancies. PGT-A is specific to IVF. RRM does not involve embryo creation outside the body, embryo biopsy, or embryo selection. The question of which embryo to transfer does not arise in RRM practice.

Anti-Müllerian Hormone (AMH)

AMH measures the number of small antral follicles currently active in the ovaries. It reflects current activity, not a fixed inventory. That distinction matters: AMH is a snapshot of this cycle's follicular activity, not a permanent verdict on reproductive potential.

What AMH does not measure is equally important. It does not measure egg quality, follicle quality, or how well ovulation is functioning. A woman with a low AMH result may still produce a competent follicle this cycle. For natural conception, one good egg per cycle is all that is required.

AMH's significance as a "low" number is largely anchored to protocols that require retrieving six to fifteen eggs at once. That is the IVF context. An RRM clinician asks a different question: what is this cycle's follicle doing? A single well-developed, well-supported follicle is the clinical target. The total pool size is a starting point for the workup, not the answer.

A low AMH result is a diagnostic signal, not a sentence. The question is why. Age is one factor. But autoimmune conditions, prior ovarian surgery, endometriosis, vitamin D deficiency, and thyroid dysfunction can all reduce AMH before age alone explains it. AMH can also change. A meta-analysis of 8 studies found DHEA supplementation significantly raised serum AMH in women with diminished ovarian reserve (Yin et al., BMC Endocrine Disorders, 2022).⁷⁷ Vitamin D repletion shows a similar effect. Treating correctable contributors is the first step, not a last resort.

AMH also has a ceiling problem. In PCOS, AMH is often markedly elevated because many small follicles accumulate without maturing. A high AMH number is not simply reassuring. It reflects a pattern of arrested follicle development that warrants investigation.

Unlike FSH, AMH does not fluctuate significantly across the menstrual cycle. It can be drawn on any cycle day, which makes it useful for tracking trends over time. But a single result should not anchor a clinical course. In RRM practice, AMH is interpreted alongside AFC, cycle chart patterns, timed hormonal panels, and a follicle maturation study when indicated. A low AMH with normal AFC and regular ovulatory cycles tells a different story than a low AMH with anovulatory cycles and a shortened luteal phase. The number alone is not the diagnosis. It is the beginning of the workup.

Antral Follicle Count (AFC)

The antral follicle count is a transvaginal ultrasound measurement taken in the early follicular phase. The sonographer counts small fluid-filled follicles, typically 2 to 10 mm in diameter, visible in both ovaries. The total is the AFC.

AFC reflects the number of follicles beginning development at the start of this cycle. A lower count indicates fewer follicles starting that cycle. Like AMH, AFC is a marker of ovarian reserve, not a standalone diagnosis. A low AFC in a 38-year-old with a surgical history is a different clinical finding than the same count in a 28-year-old with unexplained cycle irregularity. Context drives interpretation.

The right question is not how many follicles are present, but what the one dominant follicle is doing. Natural conception requires one well-developed follicle that ovulates at the right time. AFC tells the clinician what the ovary is starting with this cycle. The follicle maturation study tracks what it does next.

AFC varies more than AMH across cycles and between sonographers. Technique, equipment, and timing within the follicular phase all affect the count. A single AFC should not be used to make irreversible conclusions about prognosis. Serial measurements over two or three cycles give a more reliable picture.

In RRM practice, AFC is most useful in context. Combined with AMH, cycle chart data, and timed hormonal panels, it helps identify correctable contributors to poor follicular development: thyroid dysfunction, endometriosis, autoimmune conditions, or the suppressive effect of hormonal medications on follicle recruitment. An RRM clinician uses this picture to find and treat what is driving the finding. When ovulation support is indicated, RRM uses targeted, cycle-timed interventions designed to support this cycle's follicle, not stimulate the ovary toward a large retrieval. AFC is central to that protocol planning.

Ovarian Reserve

The ovarian reserve describes the pool of follicles currently available in the ovaries, estimated through surrogate markers: AMH, AFC, and basal FSH. Clinicians cannot count oocytes directly. These markers are proxies for follicular activity, not a balance sheet of remaining eggs.

Low reserve markers are a starting question, not a finishing answer. A low AMH or low AFC tells you the pool of visible follicles is smaller than average for age. It does not tell you why. And it does not close the door on natural conception. One competent follicle per cycle is all that is needed. The clinical question is what that follicle is doing, not how many follicles exist in the background.

Each marker captures something different. AMH reflects the number of small growing follicles actively producing the hormone. AFC counts the antral follicles visible on early-cycle ultrasound. Basal FSH rises as the pituitary increases its recruitment signal to a smaller follicular pool. Used together, these markers build a picture of current ovarian function. No single marker is definitive.

For women with reduced reserve, RRM evaluation looks for correctable contributors to the decline. Autoimmune thyroid disease accelerates follicle loss and responds to thyroid optimization. Vitamin D deficiency suppresses AMH and is correctable with repletion. Endometriosis causes direct ovarian damage through endometriomas and surgical scarring; excision addresses the structural source. Prior ovarian surgery may have reduced functional tissue, but what remains can often be supported. In documented low-DHEA-S cases, a meta-analysis of 8 studies found DHEA supplementation significantly raised AMH in women with diminished ovarian reserve.⁷⁷ These are starting points for investigation, not triage criteria.

For women with premature ovarian insufficiency, reserve assessment is part of a broader workup including genetic screening and autoimmune evaluation. For women with diminished ovarian reserve without a POI diagnosis, identifying and addressing the underlying driver is the first clinical priority. Reserve markers point toward the question. An RRM clinician builds the answer from the full picture: cycle chart, follicle maturation study, timed hormonal panels, and systemic workup.

Follicle Development

The process by which primordial follicles in the ovary are recruited, grow, and either ovulate or undergo atresia (cell death) across the menstrual cycle. Each cycle, a cohort of follicles begins maturing under FSH stimulation. Typically one dominant follicle is selected, growing to 18 to 24 mm before the LH surge triggers ovulation. The remaining follicles in the cohort regress.

Clinicians monitor follicle development directly through a follicle maturation study. Serial transvaginal ultrasounds across the follicular phase show the growth rate, timing of dominant follicle selection, and whether ovulation actually occurs or the follicle fails to rupture. That last distinction matters: a follicle can luteinize without releasing the oocyte, a condition called LUF syndrome, which standard lab tests will not detect.

Inadequate follicle development has downstream consequences. A follicle that does not reach full maturity before ovulation produces a corpus luteum with reduced progesterone output. That sets up luteal phase deficiency even in a cycle that appeared ovulatory on a basal temperature chart. Treating the luteal phase problem without addressing the follicular phase problem leaves the root cause unresolved.

In RRM practice, ovulation induction agents (clomiphene, letrozole) are used when follicle development is inadequate, timed to the follicular phase based on chart data. Monitoring with serial ultrasound confirms the response and guides trigger decisions. The goal is to restore the follicle development pattern the body was not producing on its own.

Part V: Surgical Techniques

Excision Surgery (for Endometriosis)

The surgical removal of endometriotic tissue by cutting it out, as opposed to ablation (burning/destroying it superficially). Considered the preferred surgical approach in RRM for endometriosis. A 2022 cohort study of 232 patients showed that excision improved outcomes across all 63 symptom measures evaluated (ranging from 28 to 46% improvement), while ablation only marginally improved period pain (11.3%) and heavy periods (8.5%) and worsened status in 23 of 24 quality-of-life measures. A meta-analysis found significantly greater reduction in dysmenorrhea (MD=0.99), dyschezia, and chronic pelvic pain with excision compared to ablation at 12 months.²⁷²⁸

Fulguration / Ablation / Cauterization (Endometriosis)

Superficial destruction of tissue using heat, electrical energy, or laser vaporization. As applied to endometriosis, this approach destroys the visible surface of lesions without removing the tissue or underlying disease. Evidence consistently demonstrates it is less effective than excision for symptom resolution, quality-of-life improvement, and fertility outcomes, and is associated with higher recurrence rates. Not preferred in RRM.²⁹²⁷

Adhesiolysis

Surgical division and removal of adhesions (pelvic scar tissue). In RRM and NaPro Surgery, adhesiolysis is performed meticulously, with hemostasis and anti-adhesion barrier placement to minimize adhesion reformation.¹⁰

Anti-Adhesion Barriers

Materials placed during surgery to physically separate tissue surfaces during the healing period, reducing adhesion formation. In NaPro Surgery, Gore-Tex membrane (expanded polytetrafluoroethylene) has been used extensively, with published results showing dramatic reductions in adhesion reformation scores over time.¹⁰

Tubo-tubal Anastomosis (Tubal Ligation Reversal)

Microsurgical reconnection of the fallopian tube segments following prior tubal ligation ("tubes tied"), allowing natural conception to resume. Can be performed via laparoscopy, robotic assistance, or mini-laparotomy. Pregnancy rates after tubal reversal using microsurgical techniques range from 57% to 84%. A large series found that women under 30 with ring/clip sterilization reversals achieved an 88% pregnancy rate. Success depends most strongly on the woman's age at time of reversal and the remaining tube length after reconstruction.^30313233

Vasectomy Reversal (Vasovasostomy / Vasoepididymostomy)

Microsurgical reconnection of the vas deferens after prior vasectomy, restoring the potential for natural conception. Vasovasostomy joins the two cut ends of the vas deferens and is the standard procedure. Vasoepididymostomy, a more technically demanding variant, is required when a secondary epididymal blockage has developed upstream, which is more likely with obstructive intervals greater than 10 to 15 years. Patency rates (return of sperm to the ejaculate) exceed 90% for vasovasostomy performed by experienced microsurgeons; pregnancy rates vary by obstructive interval, female partner age, and surgical technique. Vasectomy reversal is the RRM-aligned restorative alternative to surgical sperm retrieval combined with IVF/ICSI for couples seeking further pregnancies after prior vasectomy, treating the obstruction rather than bypassing it. See NeoFertility's male program for an RRM-aligned clinical model that integrates vasectomy reversal within a full couple evaluation.

Fallopian Tube Recanalization (Cannulation)

A procedure to open proximal (near the uterus) fallopian tube blockages through transcervical catheter passage, without open surgery. Often performed in conjunction with HSG. Can be done in an office or interventional radiology setting.

Neosalpingostomy / Fimbrioplasty

Laparoscopic surgical repair of distal (fimbrial end) fallopian tube damage, typically caused by pelvic inflammatory disease or prior infection. Neosalpingostomy creates a new opening in a completely blocked tube (hydrosalpinx), while fimbrioplasty reconstructs and opens a partially obstructed or agglutinated fimbrial end.

Laparoscopic Ovarian Wedge Resection (LOWR)

A surgical procedure for select PCOS cases, involving removal of a wedge of androgen-producing ovarian cortex to normalize hormonal balance and restore ovulation. Using microsurgical laser techniques, NaPro wedge resection has achieved approximately 70% pregnancy rates, over twice as effective as standard clomiphene citrate treatment (~30%) and higher than reported IVF success rates in PCOS (~23%). This surgical solution restores regular ovulation and does not carry the risk of ovarian hyperstimulation.¹⁰

Isthmocele Repair (Hysteroscopic)

Hysteroscopic treatment of a cesarean scar defect (isthmocele) by shaving and cauterizing the defect internally, reducing the depth of the niche and improving drainage of retained blood. Best suited for symptomatic patients (primarily bleeding complaints) with a residual myometrial wall thickness >5mm who do not desire future pregnancy. Associated with faster recovery but lower rates of complete bleeding resolution and does not restore wall integrity for future pregnancy.³⁴¹⁵

Isthmocele Repair (Laparoscopic)

Laparoscopic excision of the defect with multi-layer reconstruction of the uterine muscular wall. Preferred when fertility preservation is desired or when residual myometrial thickness is <5mm. Restores wall integrity for safer future pregnancy and is more likely to resolve bleeding symptoms. Longer recovery than hysteroscopic repair. Combined laparoscopic-hysteroscopic approaches are used for complex cases.¹⁶¹⁵

Myomectomy

Surgical removal of uterine fibroids (leiomyomas) while preserving the uterus. Can be performed hysteroscopically (for submucosal fibroids), laparoscopically, robotically, or via laparotomy depending on fibroid type, size, and number. RRM prefers fertility-sparing myomectomy over hysterectomy when fibroids are contributing to infertility or pregnancy loss.

Microsurgery

Surgical technique performed under microscopic magnification using fine instruments and sutures (often 6-0 to 9-0 gauge), essential for tubal anastomosis in ligation reversal and repair. Microsurgical principles include minimal tissue handling, precise hemostasis, tension-free anastomosis, and meticulous layer-by-layer closure.

Mini-laparotomy

A small (approximately 3 to 5 cm) "bikini line" incision surgery, sometimes used as an alternative to laparoscopy for procedures such as tubal ligation reversal in appropriately selected patients. Offers a smaller scar and reduced anesthesia risk compared to traditional open surgery.

Part VI: Key Conditions Addressed by RRM

Infertility

Clinically defined as failure to achieve pregnancy after 12 months of regular unprotected intercourse (6 months for women 35 years and older). In the RRM framework, infertility is understood as a symptom of one or more identifiable, underlying, treatable conditions, not a diagnosis in itself. Approximately 15% of couples worldwide are affected.⁴³⁵

Recurrent Pregnancy Loss (RPL)

Typically defined as two or more consecutive clinical pregnancy losses before 20 weeks of gestation. RPL is clinically distinct from isolated early pregnancy loss: a single loss is common and often attributable to sporadic chromosomal error, while recurrent loss warrants systematic evaluation for treatable maternal and paternal contributors. Assessment includes peripheral karyotype analysis of both partners, antiphospholipid antibody testing, uterine anatomical evaluation (SHG, HSG, or hysteroscopy), thyroid and prolactin screening, and evaluation for hereditary thrombophilias. RRM pursues identification of underlying conditions including hormonal (progesterone deficiency, thyroid dysfunction), anatomical (isthmocele, septum, fibroids), immunologic (APS, NK cell activity), and metabolic factors.³⁶³⁷

Endometriosis

A chronic inflammatory condition in which endometrial-like tissue is found outside the uterine cavity, most commonly on the ovaries, fallopian tubes, pelvic peritoneum, and rectovaginal septum. Affects approximately 1 in 10 women of reproductive age. RRM's preferred treatment is laparoscopic excision surgery, which demonstrates significantly greater improvement across all symptom domains (28 to 46% improvement range) compared to ablation, which failed to improve most symptoms and worsened quality of life in multiple measures. A key RRM principle is that hormonal suppression post-surgery (e.g., oral contraceptive pills) masks ongoing disease activity without treating the condition.²⁸²⁷

Endometrioma

An ovarian cyst formed by endometriosis, filled with old menstrual blood (colloquially called a "chocolate cyst"). Endometriomas reduce ovarian reserve and impair oocyte quality. Surgical management with excisional cystectomy is generally preferred over drainage and ablation, though ovarian reserve impact of surgery must be considered.³⁸

PCOS (Polycystic Ovary Syndrome)

A complex hormonal and metabolic disorder characterized by ovulatory dysfunction, hyperandrogenism (elevated androgens causing acne, hirsutism), and/or polycystic ovarian morphology on ultrasound. Insulin resistance and visceral adiposity are key pathophysiologic drivers, irrespective of obesity. RRM's multi-factorial approach includes lifestyle modification (5% weight loss can restore ovulation), insulin sensitization (metformin, myo-inositol), cycle charting and ovulation monitoring, targeted hormonal support, and in select cases, laparoscopic ovarian wedge resection.³⁹

PCOS Phenotypes (Rotterdam A through D)

PCOS is diagnosed when two of three Rotterdam criteria are met: ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. This produces four distinct phenotypes, each with a different metabolic and hormonal profile:

• Phenotype A (Full/Classic): All three features present. The most pronounced metabolic dysfunction and highest insulin resistance. This is the phenotype most likely to require aggressive metabolic intervention.
• Phenotype B: Ovulatory dysfunction plus hyperandrogenism, no polycystic morphology. Metabolic profile closely resembles Phenotype A.
• Phenotype C (Ovulatory): Hyperandrogenism plus polycystic morphology, with regular ovulation preserved. Milder metabolic impact than A or B.
• Phenotype D (Non-hyperandrogenic): Ovulatory dysfunction plus polycystic morphology, no hyperandrogenism. The least metabolically severe phenotype.

Phenotyping matters for treatment. Phenotypes A and B typically need insulin sensitization and metabolic correction before ovulation returns reliably. Phenotype C may respond to targeted hormonal support. Phenotype D often responds to ovulation induction without the full metabolic workup. Flying blind on phenotype means treating every PCOS presentation the same way, and that is how patients cycle through protocols for years without resolution.³⁹

Myo-Inositol

A naturally occurring carbocyclic sugar that acts as an insulin sensitizer and secondary messenger in FSH signaling. Used as a supplement in PCOS management. Evidence shows myo-inositol improves ovarian function, oocyte maturity rates, fertilization rates, and metabolic parameters (LH, FSH, HOMA-IR) in women with PCOS. A 2025 meta-analysis found statistically significant improvement in MII oocyte rate and fertilization rate, though evidence for clinical pregnancy rate improvement remains less conclusive.⁴⁰⁴¹⁴²

Uterine Isthmocele (Cesarean Scar Defect / Uterine Niche)

A myometrial defect (a pouch or indentation) in the anterior wall of the lower uterine segment (isthmus) at the site of a previous cesarean section scar, representing discontinuity of the myometrium. Caused by incomplete or defective healing of the uterine closure at the time of cesarean delivery. The defect creates a reservoir in which menstrual blood pools, then drains slowly, resulting in characteristic post-menstrual brown spotting. The retained blood creates a hostile microenvironment for sperm and may impair implantation, contributing to secondary infertility and increased miscarriage risk when the wall is thin. Prevalence is approximately 20% or more in women with prior cesarean deliveries.¹⁵¹⁶³⁴

Diagnosis: Transvaginal ultrasound (TVUS) and saline infusion sonohysterography (SIS) are the preferred diagnostic tools, both sensitive and cost-effective. SIS allows measurement of the defect dimensions and critically, the residual myometrial thickness (RMT). Treatment decisions depend on symptom profile, RMT, and future fertility desires.⁴³¹⁶¹⁵

Treatment classification:

Luteal Phase Deficiency (LPD)

A reproductive condition characterized by inadequate progesterone production or insufficient duration of the luteal phase, impairing endometrial preparation for implantation and early pregnancy support. Causes include impaired follicular development leading to insufficient corpus luteum formation, hypothyroidism, hyperprolactinemia, and GnRH pulsatility disruption. NaPro diagnosis is based on cycle-timed progesterone measurements. Treatment involves ovulation induction (to optimize follicular development and subsequent corpus luteum function) and/or progesterone supplementation beginning 3 to 4 days after the LH surge. When the deficit originates specifically from inadequate corpus luteum output, see Corpus Luteum Deficiency (CLD) for the mechanism and targeted treatment approach.⁴⁴⁴⁵

Luteal Phase (LP)

The period of the menstrual cycle following ovulation (post-peak) and preceding menstruation or implantation, typically lasting 12 to 16 days. During the luteal phase, the corpus luteum secretes progesterone to prepare the endometrium for potential implantation. A short luteal phase (<10 days) is associated with infertility and impaired endometrial maturation.⁴⁴

Corpus Luteum (CL)

A temporary endocrine structure formed from the ruptured ovarian follicle after ovulation. The corpus luteum produces progesterone and estradiol during the luteal phase. If pregnancy occurs, hCG from the implanting trophoblast rescues the corpus luteum, sustaining progesterone production until the placenta takes over (approximately 10 weeks). Inadequate CL function is the mechanism underlying Corpus Luteum Deficiency (CLD), a distinct subtype of luteal phase deficiency.⁴⁴

Luteinized Unruptured Follicle (LUF) Syndrome

A condition in which the dominant follicle reaches maturity and undergoes apparent luteinization (progesterone production begins) without actually releasing the egg (anovulation occurs despite apparent cycle regularity). LUF can cause unexplained infertility despite normal menstrual cycles and is identified by follicle tracking ultrasound showing a persistent follicle that fails to collapse at expected ovulation time.³

Anovulatory Cycles

Menstrual cycles in which ovulation does not occur, potentially presenting as apparently normal or irregular periods. Associated with PCOS, hypothalamic dysfunction, excessive exercise, low body weight, elevated prolactin, or thyroid disorders. Identified through cycle charting (absence of post-peak phase), follicle tracking, or mid-luteal progesterone testing.

Shortened Luteal Phase

A luteal phase <10 days in duration, associated with inadequate progesterone production, impaired endometrial maturation, and reduced fertility. Observed in conditions of hormonal imbalance, ovulation induction side effects, and physical stress.³

Tubal Factor Infertility

Infertility attributed to blocked, damaged, or functionally compromised fallopian tubes. Affects approximately 25 to 30% of women with infertility. Causes include prior pelvic inflammatory disease (PID), chlamydia, endometriosis, pelvic adhesions, or prior tubal surgery. RRM offers corrective surgical alternatives to IVF: fallopian tube recanalization for proximal blockage, tubo-tubal anastomosis for mid-segment disease, and neosalpingostomy/fimbrioplasty for distal disease.¹

Hydrosalpinx

A fluid-filled, distended, obstructed fallopian tube, typically the result of prior infection or endometriosis causing complete distal tubal occlusion. Hydrosalpinges are associated with reduced IVF success rates (the fluid may be embryotoxic). RRM options include neosalpingostomy (opening and repairing the tube) when tube quality is adequate, or salpingectomy if repair is not feasible.

Fallopian Tube Anatomy Reference

The fallopian tube has four anatomical segments, each relevant to RRM diagnosis and surgery:⁴⁶⁴⁷

• Interstitial (Intramural): Segment passing through the uterine wall, narrowest portion, most difficult to cannulate
• Isthmus: Narrow segment adjacent to the uterus; site of distal ligation in many sterilization procedures; most favorable for anastomosis reversal
• Ampulla: Widest, longest segment (5 cm, diameter up to 1 cm); most common site of fertilization and ectopic pregnancy⁴⁷
• Infundibulum / Fimbriae: Open, funnel-shaped distal end with finger-like fimbriae that sweep the ovulated egg into the tube; damage here causes hydrosalpinx

Pelvic Adhesions (Scar Tissue)

Bands of fibrous tissue that form between pelvic structures following inflammation, infection, endometriosis, or prior surgery. Adhesions can distort pelvic anatomy, restrict tube and ovarian mobility, cause chronic pelvic pain, and impair fertility. RRM treatment involves meticulous laparoscopic adhesiolysis with anti-adhesion barrier placement.

Adenomyosis

A condition in which endometrial-like glands and stroma are present within the myometrium (uterine muscle wall), causing the uterus to enlarge and the junctional zone (the inner myometrium) to thicken. Adenomyosis is associated with heavy, painful periods and impaired fertility. A meta-analysis found women with adenomyosis had a 28% decreased probability of clinical pregnancy via IVF/ICSI compared to women without it, and higher miscarriage rates (OR 2.17). RRM approaches include hormonal management, and in selected cases, surgical resection of focal lesions.⁴⁸⁴⁹⁵⁰

Uterine Fibroids (Leiomyomas)

Benign smooth muscle tumors of the uterus. Classification by location significantly affects fertility impact:

• Submucosal: Protrude into the uterine cavity; most strongly associated with infertility and pregnancy loss; treated hysteroscopically
• Intramural: Within the uterine wall; may impair fertility when large or distorting
• Subserosal: On the outer uterine surface; least impact on fertility

RRM approach: myomectomy (fertility-preserving fibroid removal) when fibroids are contributing to reproductive problems.

Uterine Septum

A congenital structural abnormality in which a fibromuscular wall (septum) divides part or all of the uterine cavity. Associated with increased risk of miscarriage (due to poor septum vascularization impairing implantation) and preterm labor. Treated hysteroscopically by incising and resecting the septum.

Intrauterine Adhesions (Asherman's Syndrome)

Scar tissue within the uterine cavity, typically following uterine trauma (e.g., D&C, myomectomy, infection). Ranges from mild adhesions to obliteration of the cavity. Diagnosed by SIS, HSG, or hysteroscopy. Treated by hysteroscopic adhesiolysis with post-operative estrogen therapy to promote re-epithelialization.

Chronic Endometritis (CE)

A persistent, low-grade inflammatory condition of the endometrial lining caused by abnormal colonization of the endometrium by bacteria (e.g., Enterococcus, E. coli, Streptococcus). Often subclinical (no obvious symptoms). CE is significantly associated with recurrent implantation failure and recurrent pregnancy loss. Diagnosed by office hysteroscopy (strawberry-pattern micropolypoid endometrium) confirmed by CD138 immunohistochemistry on endometrial biopsy. Treated with targeted antibiotics (typically doxycycline, amoxicillin, or based on culture). A cohort study showed the biopsy/treatment group had significantly higher chances of pregnancy (HR 2.28) and live birth (HR 2.76) compared to hysteroscopy-only controls.⁵¹²⁶

Antiphospholipid Syndrome (APS)

An autoimmune condition in which antiphospholipid antibodies (including lupus anticoagulant, anticardiolipin antibodies (aCL), and anti-beta-2 glycoprotein I antibodies) cause a hypercoagulable state that can result in thrombosis and pregnancy complications including recurrent miscarriage, fetal loss, and stillbirth. Diagnosis requires both clinical criteria (vascular thrombosis or pregnancy morbidity) and laboratory criteria (confirmed antibodies on two occasions 12 or more weeks apart). RRM treatment: low-dose aspirin initiated preconceptionally, plus prophylactic-dose heparin (LMWH) from a positive pregnancy test through delivery. Multiple guidelines (EULAR, ESHRE, ACCP, ACOG) support this protocol.⁵²³⁶

Autoimmune/Thrombophilic Disorders (as RPL Causes)

Beyond APS, RRM evaluates for inherited thrombophilias (Factor V Leiden, prothrombin mutation, protein C/S deficiency), natural killer (NK) cell dysregulation, and systemic autoimmune conditions (antithyroid antibodies, antinuclear antibodies) in women with RPL. Assessment guides individualized medical therapy. See Clotting Disorder / Thrombophilia for a full breakdown of inherited vs acquired subtypes, risk stratification, and treatment approach.³⁷

Methylated Folate (L-Methylfolate) and MTHFR

Methylated folate (5-methyltetrahydrofolate, 5-MTHF) is the biologically active form of folate that participates directly in homocysteine remethylation, DNA synthesis, and the methylation reactions that matter most in early embryonic development. Most prenatal vitamins and fortified foods contain synthetic folic acid, not 5-MTHF. To become active, folic acid requires enzymatic conversion by methylenetetrahydrofolate reductase (MTHFR). Two common MTHFR gene variants, C677T and A1298C, reduce that enzyme's activity. Reduced activity means impaired folate metabolism. Impaired folate metabolism can raise homocysteine, increase thrombophilic risk, and contribute to recurrent pregnancy loss in affected individuals. This is not a rare edge case. MTHFR variants are common, and most patients who carry them have never been tested. RRM protocols specify L-methylfolate preconceptionally for women with known MTHFR variants, recurrent miscarriage, or elevated homocysteine. That means skipping the conversion step entirely and delivering the active form directly.

Varicocele

An abnormal dilation of the veins within the scrotum (pampiniform plexus), present in 15% of the male population and in approximately 35% of men evaluated for infertility. Varicoceles raise scrotal temperature and increase oxidative stress, impairing spermatogenesis and increasing sperm DNA fragmentation. Varicocele repair (varicocelectomy) results in significant improvement in semen parameters in 60 to 80% of men, with natural pregnancy rates of 43% at one year and 69% at two years when female factors are excluded. Microsurgical subinguinal varicocelectomy is the preferred technique, associated with the highest spontaneous pregnancy rates and lowest complication rates.^53545556

Male Factor Infertility

Infertility attributable to male reproductive factors, estimated to contribute to approximately 50% of infertility cases when assessed comprehensively. RRM evaluates male partners with semen analysis, sperm DNA fragmentation testing, hormonal testing, and where indicated, surgical evaluation (varicocele assessment). Treatments include varicocele repair, lifestyle modification, antioxidant therapy, hormonal correction, and in severe cases (azoospermia), microsurgical sperm retrieval.³⁵

Oligospermia / Asthenospermia / Teratospermia

Reduced sperm parameters defined by WHO reference values:

• Oligospermia: Sperm concentration <16 million/mL
• Asthenospermia: Progressive motility <30%
• Teratospermia: Normal morphology <4% (Kruger strict criteria)

Often co-exist; combined deficits are termed oligoasthenoteratospermia (OAT syndrome).

Azoospermia

Complete absence of sperm in the ejaculate. Classified as:

• Obstructive: Sperm production is normal but outflow is blocked (e.g., prior vasectomy, epididymal blockage); potentially correctable surgically
• Non-obstructive: Impaired spermatogenesis (e.g., Sertoli cell-only syndrome, maturation arrest); may still have focal sperm production accessible via testicular sperm extraction (TESE)

Oxidative Stress / Reactive Oxygen Species (ROS)

An imbalance between pro-oxidant species (ROS, reactive nitrogen species) and antioxidant defenses. At physiological levels, ROS play important roles in folliculogenesis, oocyte maturation, capacitation, and embryo development. Excess ROS, however, damages sperm DNA, impairs sperm motility, disrupts oocyte quality, damages embryos, and is linked to endometriosis, PCOS, unexplained infertility, recurrent miscarriage, and preeclampsia. RRM addresses oxidative stress through targeted antioxidant supplementation (vitamin C, E, CoQ10, zinc, selenium, L-carnitine, N-acetylcysteine), lifestyle modification (smoking cessation, weight management), and treatment of underlying conditions.⁵⁷⁵⁸³⁵

Sperm DNA Fragmentation Index (DFI): Extended

High DFI (generally defined as >25 to 30%) is independently associated with poor reproductive outcomes, including failed natural conception and IUI, and is a significant predictor of miscarriage. Treatment strategies in RRM include: antioxidant supplementation (reduces DFI and improves pregnancy rates); varicocele repair (meta-analysis: 3.37% mean DFI reduction post-repair); lifestyle changes (smoking cessation, weight optimization, stress reduction); treating genital tract infections; and shortened ejaculatory abstinence periods. Testicular sperm extraction yields sperm with lower DFI than ejaculated sperm in severe cases.²⁰²¹¹⁹

Hormonal Abnormalities

Imbalances disrupting the menstrual cycle, ovulation, or early pregnancy. RRM diagnoses these through cycle-timed blood tests guided by fertility charting. Key hormones evaluated include:

• FSH (Follicle-Stimulating Hormone): Stimulates follicular development; elevated early-cycle FSH indicates diminished ovarian reserve
• LH (Luteinizing Hormone): Surge triggers ovulation; chronically elevated in PCOS
• Estradiol (E2): Primary estrogen; supports follicular development, cervical mucus production, and endometrial proliferation
• Progesterone (P4): Luteal phase hormone critical for endometrial receptivity and early pregnancy; measured at post-peak +7 in NaPro protocols
• hCG (Human Chorionic Gonadotropin): Produced by the implanting trophoblast; sustains the corpus luteum; measured for early pregnancy confirmation and monitoring
• Prolactin: Elevated levels (hyperprolactinemia) suppress LH/FSH pulsatility, impairing ovulation and the luteal phase
• AMH (Anti-Mullerian Hormone): Secreted by ovarian granulosa cells; marker of ovarian reserve; low in diminished ovarian reserve (DOR)

Hypothyroidism / Subclinical Hypothyroidism

Deficiency of thyroid hormone, most commonly due to autoimmune Hashimoto's thyroiditis in iodine-sufficient regions. Even subclinical hypothyroidism (elevated TSH with normal free T4) is associated with increased miscarriage risk, impaired fertility, and potential adverse pregnancy outcomes. RRM screens thyroid function and optimizes thyroid status before and during attempts at conception.

Hyperprolactinemia

Elevated serum prolactin levels, which suppress hypothalamic GnRH pulsatility, thereby reducing LH and FSH secretion. Results in ovulatory dysfunction, luteal phase insufficiency, and impaired fertility. Common causes include pituitary microadenoma (prolactinoma), hypothyroidism, and medications. Treated with dopamine agonists (cabergoline, bromocriptine) or management of the underlying cause.³

Premature Ovarian Insufficiency (POI)

Loss of normal ovarian function before age 40, resulting in irregular or absent menstruation, infertility, and hormonal deficiencies mimicking menopause. Affects approximately 1% of women under 40. Causes include autoimmune, genetic (fragile X premutation), iatrogenic (chemotherapy, radiation), and idiopathic. RRM evaluation and management includes transdermal estrogen for physiological hormone replacement, fertility-preservation strategies, and treatment of underlying autoimmune conditions.³

Diminished Ovarian Reserve (DOR)

A reduction in the quantity (and sometimes quality) of oocytes in the ovaries, leading to decreased fertility potential. Diagnosed by elevated FSH, low AMH, and low antral follicle count (AFC) on ultrasound. DOR is age-related but can occur prematurely. RRM takes an aggressive diagnostic approach, evaluating for autoimmune, mitochondrial, inflammatory, and lifestyle contributors. See Ovarian Reserve for interpretation of reserve markers in clinical context.³

Insulin Resistance / Metabolic Dysfunction

A state of impaired cellular response to insulin, common in PCOS (present in 50 to 70% of cases) and an independent contributor to ovulatory dysfunction, infertility, and miscarriage. RRM addresses through dietary modification (low glycemic index diet), exercise, targeted supplementation (myo-inositol, alpha-lipoic acid, CoQ10), and medication (metformin) when indicated.³⁹³

Secondary Infertility

Difficulty conceiving after a prior pregnancy. RRM re-evaluates comprehensively for new or evolving conditions, including C-section scar isthmocele, new-onset endometriosis or adhesions, chronic endometritis, postpartum thyroiditis, or hormonal shifts.³

Unexplained Infertility

A clinical label given when no cause is identified through standard evaluation. RRM does not accept this as a final diagnosis but pursues deeper investigation including cycle-timed hormone panels, advanced sperm testing (SDF), chronic endometritis screening, immunologic testing, and laparoscopic assessment for subtle pelvic pathology.¹

Time to Pregnancy (TTP)

The number of menstrual cycles or months required to achieve a clinical pregnancy in a couple attempting conception. In the general fertile population, approximately 80% of couples conceive within six cycles and 90% within twelve cycles. TTP is an important framing concept in RRM: procedural approaches are often reported as per-cycle success rates, whereas RRM is evaluated by cumulative outcomes across the full course of diagnosis and treatment. Published NaProTECHNOLOGY cohort studies report cumulative live-birth rates at 24 and 36 months, reflecting the restorative time horizon in which underlying conditions are corrected and fertility resumes naturally.¹⁰¹¹

Cervical Factor Infertility

Impaired cervical mucus production or quality, reducing sperm survival and transport. Contributing factors include low estrogen, prior cervical procedures (LEEP, cone biopsy), cervical inflammation, or mucus antibodies. RRM optimizes cervical mucus through hormonal support of estrogen adequacy and treatment of underlying hormonal deficiencies.

Poor Cervical Mucus Production

Cervical mucus that is insufficient in quantity, too thick, or does not exhibit fertile-quality characteristics (clear, stretchy, lubricative) near ovulation. Fertile mucus creates a protective environment for sperm, filtering defective sperm and providing a reservoir that sustains sperm for up to 5 days. Poor mucus production reduces the effective fertile window and impairs sperm ascent.

Endometrial Thickness

The measurement of the uterine lining as assessed by transvaginal ultrasound. Optimal endometrial thickness for implantation is generally 7 to 8 mm or more with a trilaminar (three-layer) pattern. Thin endometrium is associated with reduced implantation rates and is investigated for causes including prior uterine surgery, estrogen deficiency, poor blood flow, and Asherman's syndrome.

Endometrial Hyperplasia

A pathologic overgrowth of the endometrium characterized by increased number and crowding of endometrial glands, usually caused by prolonged estrogen exposure without sufficient progesterone (unopposed estrogen). This condition is not cancer, but some forms are precancerous and can progress to endometrial adenocarcinoma if untreated. Classified as "without atypia" (lower risk) or "atypical" (endometrial intraepithelial neoplasia, higher cancer risk). Often presents with abnormal uterine bleeding: heavy, frequent, irregular, or postmenopausal.

RRM relevance: Endometrial hyperplasia is driven by hormonal imbalance, especially chronic or intermittent anovulation and other causes of unopposed estrogen: PCOS, obesity, estrogen-only therapy, and estrogen-secreting tumors. In RRM practice, cycle charting identifies anovulatory patterns early, and targeted progesterone therapy addresses the hormonal imbalance causing the overgrowth. For women with atypical hyperplasia who desire fertility, intensive progestin-based therapy with close surveillance may be an option before considering hysterectomy.

Window of Implantation (WOI)

The hormonally determined period during the secretory phase of the menstrual cycle (approximately cycle days 19 to 23 in a standard 28-day cycle) during which the endometrium is maximally receptive to embryo implantation. The WOI is precisely regulated by estrogen and progesterone and is displaced in approximately 20 to 25% of women with recurrent implantation failure, identifiable via ERA testing.²⁴²³

Postpartum Fertility Issues

Fertility challenges arising in the postpartum period, including lactational amenorrhea (anovulation during breastfeeding due to prolactin elevation), retained placenta fragments, postpartum thyroiditis, hormonal dysregulation, and uterine scar defects (isthmocele from cesarean delivery). RRM offers specialized postpartum evaluations to identify and address these causes.³

Chronic Pelvic Pain (CPP)

Pelvic pain lasting 6 months or more, often involving multiple overlapping causes: gynecologic (endometriosis, adenomyosis, pelvic adhesions), musculoskeletal, urologic (interstitial cystitis), gastrointestinal, neuropathic, and psychosocial. RRM addresses gynecologic causes surgically (excision, adhesiolysis) while recognizing the multidimensional nature of CPP and coordinating interdisciplinary care.

Luteinizing Hormone (LH)

Luteinizing hormone is produced by the anterior pituitary gland. It drives two essential reproductive events: the mid-cycle LH surge, which triggers ovulation, and ongoing stimulation of the corpus luteum to produce progesterone after ovulation.

The LH surge is the signal that ovulation is imminent. Most urinary LH tests detect this surge 24 to 36 hours before follicle rupture. Timing intercourse or insemination to the surge is the basis of most ovulation-detection approaches. But surge detection is not the same as confirmed ovulation. In LUF syndrome, the surge occurs normally while the follicle fails to rupture.

Baseline LH levels on cycle day 2 or 3 are part of an RRM hormonal panel. An elevated LH-to-FSH ratio is one finding consistent with PCOS. Persistently elevated LH outside the expected surge window can reflect hypothalamic disruption, stress, or thyroid dysfunction.

LH is also used therapeutically in RRM practice. Cycle-timed hCG injections, which mimic the action of LH, can support corpus luteum function and assist with follicle release in cases where the endogenous surge is insufficient. This is a targeted, restorative intervention, not suppression.

Without cycle chart data anchoring the timing, LH values lose much of their interpretive value. A single LH drawn without knowing where the patient is in her cycle is close to meaningless. Chart-based medicine avoids this problem.

Follicle-Stimulating Hormone (FSH)

Follicle-stimulating hormone is released by the anterior pituitary gland in response to signals from the hypothalamus. Its primary job is to stimulate the growth and maturation of ovarian follicles. Each month, FSH recruits a cohort of follicles, one of which typically becomes dominant and proceeds to ovulation.

Basal FSH, drawn on cycle day 2, 3, or 4, is a standard component of an ovarian reserve panel. An elevated basal FSH signals that the pituitary is working harder than normal to recruit follicles. This elevation reflects reduced ovarian sensitivity, which is often an early indicator of declining reserve. The threshold for "elevated" varies by laboratory and by age.

FSH is most useful in combination with other markers. A single elevated FSH in an otherwise normal cycle may be less meaningful than persistently elevated FSH across multiple cycles. Similarly, FSH must be read alongside AMH, AFC, and estradiol on the same draw date. Estradiol, if elevated on day 3, can suppress FSH artificially and mask the true reserve status.

In men, FSH plays a parallel role: it stimulates the Sertoli cells of the testes, which support sperm production. Elevated FSH in a man with low sperm counts often signals primary testicular failure, meaning the testes are not responding adequately despite the pituitary's signal. This finding changes the clinical approach significantly.

RRM clinicians use FSH trends over time rather than single-point snapshots. A rising FSH in a woman in her mid-30s is a call to investigate and act, not to reassign her to a lower-prognosis category and recommend moving to donor egg.

Human Chorionic Gonadotropin (hCG)

Human chorionic gonadotropin is produced by the developing trophoblast immediately after implantation. Its rise in early pregnancy is the basis of every pregnancy test. But hCG also has important therapeutic applications in RRM practice that extend well beyond diagnosis.

Structurally, hCG closely resembles LH. It binds the same receptors. This means exogenous hCG can substitute for the mid-cycle LH surge to trigger ovulation, or it can provide ongoing luteal phase support after ovulation when the corpus luteum needs reinforcement. Both uses are part of restorative care.

In recurrent pregnancy loss, low early-pregnancy hCG can reflect inadequate trophoblast support, which is often related to insufficient progesterone or underlying endometrial pathology. Targeted hCG supplementation in early pregnancy has been studied as a support strategy for women with a history of recurring loss. Quenby and Farquharson published a controlled trial examining this approach in 1994.⁶⁰ The rationale is restorative: support the corpus luteum and the developing pregnancy rather than waiting for it to fail.

hCG injections are also used in NaProTechnology protocols to assist with ovulation induction and to support the luteal phase in women with documented deficiency. The timing is cycle-charted, not arbitrary. That precision is what makes the intervention restorative rather than generic hormonal loading.

Serial quantitative hCG levels in early pregnancy are one of the most important early monitoring tools in RRM care. A doubling time that is slower than expected, or a plateau, prompts early investigation and intervention rather than a "wait and see" approach.

Natural Killer (NK) Cells

Natural killer cells are a type of innate immune cell found throughout the body. In the uterine lining, a specialized population called uterine natural killer cells (uNK cells) plays a distinct role during implantation. These cells help remodel the spiral arteries of the uterus and regulate the immune environment at the maternal-fetal interface. They are not simply immune attackers. They are part of the architecture of a successful implantation.

The relationship between NK cell activity and fertility is not straightforward. In endometriosis, altered NK cell function has been documented: women with endometriosis show reduced cytotoxic activity against autologous endometrial cells, which may allow ectopic tissue to survive and proliferate.⁶¹ This immune dysregulation is one mechanism by which endometriosis may compromise implantation and contribute to both infertility and recurrent loss.

Peripheral blood NK cell testing measures circulating NK cells, not uterine NK cells. The two populations behave differently. Elevated peripheral NK cell counts do not reliably predict uterine NK cell dysfunction. Clinicians who draw conclusions about implantation failure from blood NK counts alone are measuring the wrong compartment.

RRM clinicians who evaluate implantation failure look at the uterine environment directly, through endometrial biopsy, progesterone levels, and cycle timing, rather than relying on peripheral markers that have uncertain clinical correlation. Treating elevated NK cell counts on a blood test without diagnosing the underlying cause is not restorative medicine.

When genuine immune dysregulation is contributing to implantation failure or recurrent loss, addressing the root condition matters. In endometriosis-related cases, excision of disease followed by targeted luteal phase support is the restorative approach. The goal is a uterine environment capable of sustaining pregnancy, not immune suppression layered on top of an unaddressed diagnosis.

Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a cyclical cluster of physical and emotional symptoms occurring in the luteal phase of the menstrual cycle and resolving with the onset of menstruation. Common symptoms include bloating, breast tenderness, mood changes, headache, and fatigue. These symptoms recur predictably in relation to ovulation and are absent in the follicular phase.

Standard medicine often treats PMS as an inevitability. RRM treats it as a signal. PMS that is severe, recurrent, or cycle-consistent warrants investigation. In many cases, the underlying driver is luteal phase deficiency: inadequate progesterone production by the corpus luteum following ovulation. Thyroid dysfunction, particularly subclinical hypothyroidism, is another frequent and underdiagnosed contributor.

RRM clinicians evaluate cycle charts alongside serum hormone levels drawn at timed intervals across the luteal phase. This approach distinguishes PMS driven by hormonal deficiency from PMDD (premenstrual dysphoric disorder), a more severe, psychiatrically classified condition. The distinction matters because the treatment pathways differ.⁶⁶

Hilgers documented that women with PMS show significantly decreased luteal phase progesterone, estradiol, and beta-endorphin levels compared to controls, and that cycle-timed hormonal support achieved marked improvement in the majority of cases.⁶⁷

PMS is information. It points toward a hormonal pattern. The clinician's job is to read it.

See also: Luteal Phase Deficiency, Corpus Luteum, Hypothyroidism.

Thyroid-Stimulating Hormone (TSH)

Thyroid-stimulating hormone (TSH) is secreted by the anterior pituitary gland and drives the thyroid gland to produce thyroxine (T4) and triiodothyronine (T3). When thyroid output falls, TSH rises. When output is high, TSH falls. It is the primary clinical marker for thyroid function.

Standard laboratory reference ranges for TSH span roughly 0.5 to 4.5 mIU/L. "Within normal limits" is not the same as "optimal for reproduction." Research published in the Journal of Clinical Endocrinology and Metabolism found that higher TSH levels within the standard normal range were independently associated with unexplained infertility.⁶⁸ For women trying to conceive, many RRM clinicians target a TSH below 2.5 mIU/L, because subclinical hypothyroidism at higher values within the standard range carries documented risk for anovulation, luteal phase insufficiency, and miscarriage.

The practical implication: a TSH of 3.8 mIU/L may not trigger treatment from a general practitioner. An RRM clinician may read that same value as a contributor to cycle dysfunction and act on it.

TSH should be evaluated alongside free T4, free T3, and thyroid antibody levels when reproductive concerns are present. Autoimmune thyroid disease can affect fertility even when TSH remains near-normal.

See also: Hypothyroidism.

Body Mass Index (BMI)

Body mass index (BMI) is a calculation of weight relative to height (kg/m²). It functions as a population-level screening tool, not a precise measure of individual metabolic health. BMI does not account for muscle mass, body composition, fat distribution, or ethnicity-based variation. Clinicians use it as one data point, not a verdict.

At the extremes, BMI has measurable effects on reproductive function. A BMI below 18.5 can suppress the hypothalamic-pituitary axis, reducing gonadotropin release and preventing ovulation. A BMI above 30 drives insulin resistance and elevated androgens, both of which blunt ovulatory signaling, particularly in women with PCOS. Research confirms that both low and high preconception BMI elevate subfertility risk independently of other factors.⁶⁹ Metabolic contributors to fertility disorders deserve systematic evaluation rather than a single number.⁷⁰

RRM does not moralize about weight. It identifies the metabolic pathway affecting ovulation and addresses it directly. Is this hypothalamic suppression from under-fueling? Is this insulin-mediated androgen excess? The answer changes the clinical approach.

See also: PCOS, Insulin Resistance, Anovulatory Cycles.

Molimina

Molimina (from Latin: exertions) describes the cluster of mild physiological symptoms that occur in the late luteal phase as a direct result of progesterone production by the corpus luteum. Typical symptoms include mild breast tenderness, a sense of pelvic fullness, subtle fluid retention, and slight shifts in energy or mood. These symptoms appear predictably before menstruation and resolve when it begins.

Molimina is a positive diagnostic sign, not a pathological condition. When a patient reports these symptoms in a predictable cycle pattern correlated with peak-day timing, the clinician knows ovulation occurred and that a functioning corpus luteum formed. No serum progesterone test is required to confirm this. The chart confirms it.

This distinguishes molimina from PMS. PMS is a symptom complex that often reflects hormonal imbalance, particularly luteal phase deficiency. Molimina reflects normal luteal progesterone activity. Mild premenstrual awareness is not a problem to be eliminated. It is the body reporting that ovulation happened.

In NaProTechnology-informed practice, the Creighton Model chart captures the cycle pattern across months. The presence of consistent molimina, correlated with peak day, is clinical information. Absence of molimina in a patient who previously experienced it can signal a deteriorating luteal phase.

See also: Corpus Luteum, Peak Day, Luteal Phase, Luteal Phase Deficiency, Anovulatory Cycles.

Clinical Endorphin Deficiency

A state of insufficient endogenous opioid (endorphin) activity that disrupts hormonal signaling involved in ovulation, immune regulation, and reproductive function. Endorphins modulate the hypothalamic-pituitary axis, influencing GnRH pulsatility and downstream LH and FSH secretion. Deficient endorphin tone is associated with irregular cycles, poor follicular response, and implantation failure in some populations.

The condition lacks a standardized diagnostic threshold. In NeoFertility protocols, clinical endorphin deficiency is inferred from the clinical pattern: reduced ovarian responsiveness, thin endometrium, and failure to conceive despite otherwise normal-appearing diagnostics. Low-dose naltrexone at 4.5 mg nightly addresses this by transiently blocking opioid receptors. The temporary blockade triggers a compensatory rebound in endorphin production. See Low-Dose Naltrexone (LDN) for the mechanism and published outcomes data.

This is an area where RRM practice is ahead of the published literature. The physiological rationale is established. Large controlled trials do not yet exist. Clinicians using LDN for this indication are making a clinically reasoned judgment from mechanism, case series, and cohort data. That is honest medicine. It is also different from saying the question is settled.

Clotting Disorder / Thrombophilia

A heritable or acquired tendency toward excessive blood clotting that can impair placentation and contribute to pregnancy loss. Inherited thrombophilias include Factor V Leiden mutation, prothrombin G20210A mutation, and protein C, protein S, or antithrombin deficiency. Acquired thrombophilia includes antiphospholipid syndrome (APS), which involves antibodies that interfere with phospholipid-binding proteins critical to normal coagulation and placental function.

The mechanism of pregnancy loss is primarily vascular. Microthrombi in the early placental vasculature impair the implantation bed and restrict blood flow to the developing embryo. Not all inherited thrombophilias carry the same risk level. Factor V Leiden heterozygosity confers modest increased risk; homozygous mutations and combined thrombophilias carry substantially higher risk.

RRM evaluation for thrombophilic conditions is part of the standard RPL workup and is also considered in women with a history of placental abruption, late fetal loss, or unexplained preterm birth. Treatment, when indicated, typically involves low-molecular-weight heparin during pregnancy, sometimes combined with low-dose aspirin. See Autoimmune/Thrombophilic Disorders for the full RPL context and evaluation protocols.⁷⁵

Early Pregnancy Loss

The loss of a clinically confirmed pregnancy before 13 weeks of gestation. Early pregnancy loss is the most common complication of pregnancy, occurring in approximately 10 to 20% of confirmed pregnancies. The majority result from chromosomal abnormalities in the embryo. But recurrent loss, defined as two or more losses, warrants systematic evaluation for treatable maternal factors.

This distinction is central to RRM's approach. A single loss is statistically common and often attributable to sporadic chromosomal error. Two or more losses define Recurrent Pregnancy Loss (RPL), a separate clinical entity with a different differential diagnosis and a different evaluation protocol. Conflating a single loss with recurrent loss understates the clinical significance of the pattern and delays workup.

Treatable causes of early pregnancy loss include progesterone deficiency, thyroid dysfunction, uterine abnormalities (septum, submucous fibroids, isthmocele), antiphospholipid syndrome, inherited thrombophilias, and chronic endometritis. RRM protocols address these systematically rather than attributing losses to chance and advising the couple to try again without investigation.

Early pregnancy loss is distinguished from biochemical pregnancy (positive hCG with no ultrasound confirmation) and from stillbirth (fetal loss at or after 20 weeks). Each carries its own evaluation framework. RRM does not collapse these into a single category.

Corpus Luteum Deficiency (CLD)

Insufficient progesterone production from the corpus luteum during the luteal phase, resulting in inadequate endometrial support for implantation and early pregnancy. CLD is a structural problem at the level of the corpus luteum itself. Clinicians distinguish CLD from Luteal Phase Deficiency (LPD): LPD describes the hormonal pattern (low or short progesterone output), while CLD names the anatomical source of that deficit.

The corpus luteum forms from the ruptured follicle after ovulation. Its capacity to produce progesterone depends heavily on how well the follicle developed beforehand. A follicle that was small at ovulation, grew slowly, or was triggered prematurely produces a suboptimal corpus luteum. Treating luteal phase deficiency with progesterone supplementation alone, without addressing the follicular phase problem, manages the downstream effect but leaves the upstream cause untreated.

NaProTechnology identifies CLD through cycle-timed progesterone profiling: multiple measurements taken across the luteal phase rather than a single mid-luteal draw. A flat or declining progesterone curve identifies corpus luteum failure specifically. Treatment in RRM practice combines optimizing follicular development (ovulation induction when indicated) with post-Peak progesterone support timed to the chart.

Part VII: Overlapping Disciplines

Reproductive Endocrinology

The study of hormonal regulation of reproduction, encompassing the hypothalamic-pituitary-gonadal axis and its downstream effects on ovulation, implantation, and pregnancy maintenance. In RRM, reproductive endocrinology is practiced with cycle-timed hormone evaluation (blood draws ordered at specific cycle phases identified by charting) rather than single random draws that miss dynamic hormonal patterns. This discipline is core to all RRM approaches, providing the diagnostic foundation for targeted medical treatment.³

Reproductive Immunology

The investigation of the immune system's role in implantation failure, recurrent miscarriage, and conditions such as endometriosis. Central to the NeoFertility protocol, reproductive immunology evaluation includes NK cell panels (natural killer cell activity), antiphospholipid antibody testing, food antibody screening, and chronic endometritis workup. Treatment modalities include low-dose naltrexone (LDN), intralipid infusions, corticosteroids, and anticoagulation therapy.¹

Restorative Andrology

Male-partner evaluation and treatment within the RRM framework, focused on identifying and correcting the underlying causes of male factor infertility. Restorative andrology investigates varicocele, hormonal imbalance, oxidative stress, infection, sperm DNA fragmentation, and lifestyle contributors rather than bypassing male factor with intracytoplasmic sperm injection (ICSI). Treatment includes varicocelectomy, antioxidant therapy, hormonal correction, and lifestyle modification.³⁵⁵³

Minimally Invasive Gynecologic Surgery (MIGS)

Laparoscopic and hysteroscopic surgical techniques used in RRM for excision of endometriosis, adhesiolysis, isthmocele repair, myomectomy, and tubal surgery. MIGS emphasizes tissue preservation and fertility-sparing approaches, removing pathology while maintaining or restoring the structural and functional integrity of reproductive organs. Robotic-assisted and mini-laparotomy techniques are included under this umbrella.¹⁰¹⁷

Cycle-Timed Diagnostics

The core RRM concept of ordering hormone panels, ultrasounds, and other tests at specific points in the menstrual cycle rather than on random calendar dates. By timing bloodwork to charting-identified events (e.g., post-peak day +7 for progesterone, early follicular phase for FSH and estradiol), clinicians detect luteal phase deficiency, anovulation, and hormonal patterns that random-draw testing misses. Cycle-timed diagnostics is what makes fertility charting clinically actionable, not merely observational.³¹

Pelvic Floor Physical Therapy

Specialized rehabilitation addressing musculoskeletal contributors to chronic pelvic pain, dyspareunia, and voiding dysfunction. Part of the multidisciplinary RRM care team for patients with overlapping gynecologic and musculoskeletal pathology. Pelvic floor therapists assess and treat hypertonic pelvic floor muscles, myofascial trigger points, scar tissue restrictions, and neuromuscular dysfunction that coexist with conditions like endometriosis and adenomyosis.

FertilityCare Practice

The professional discipline of teaching fertility awareness charting methods to patients. FertilityCare Practitioners (FCPs) are credentialed through the American Academy of FertilityCare Professionals (AAFCP) and serve as the charting education arm of the NaPro care model. FCPs teach the Creighton Model FertilityCare System and provide ongoing follow-up to ensure accurate charting. In RRM broadly, certified instructors for each method (FEMM Teachers, Marquette instructors, sympto-thermal educators) fill an equivalent role within their respective clinical systems.⁷

Functional and Nutritional Medicine

Assessment and optimization of nutritional status, metabolic markers, and lifestyle factors as part of reproductive health restoration. Includes evaluation of vitamin D, folate, B12, iron, zinc, omega-3 fatty acids, insulin resistance, inflammatory markers, and environmental toxin exposure. In RRM, nutritional and metabolic assessment is not adjunctive. It is part of the core diagnostic workup, addressing modifiable factors that directly affect ovulation, implantation, and pregnancy maintenance.³

FertilityCare Practitioner (FCP)

A FertilityCare Practitioner is a trained educator who teaches the Creighton Model FertilityCare System to individual clients and couples. FCPs are not physicians. They are the entry point into NaProTechnology care. They teach chart reading, support clients through cycle tracking, and prepare the standardized chart documentation that NaPro-trained physicians use for clinical decision-making.

The FCP role is defined and credentialed through the FertilityCare Centers of America training program. Training includes instruction in the biological markers of the Creighton Model, chart interpretation, client education, and the interface between chart findings and medical referral. After initial training, FCPs maintain ongoing professional development.

The distinction between an FCP and a physician matters clinically. The FCP builds the chart. The physician reads it in context. Neither is redundant. In NaProTechnology practice, the physician who has never seen the chart is practicing without the most important data set the patient can provide. The chart is the clinical record of what the cycle is doing over time, not a single hormone level drawn at an arbitrary point.⁶⁴

For couples using Creighton Model charting to achieve pregnancy, the FCP teaches them to identify the fertile window, observe and record biomarkers accurately, and recognize patterns that may indicate underlying conditions worth evaluating. The FCP communicates those patterns to the physician. This is the communication infrastructure of restorative care.

FCPs can also help couples using the Creighton Model to avoid pregnancy. The same chart that guides fertility-seeking couples guides those seeking to space pregnancies, without suppressive medications. The FCP's role is the same in both contexts: teach accurate observation and support the couple in using their own fertility data.

Finding an FCP is typically the first concrete step for couples who want to engage with NaProTechnology or RRM care. An RRM clinician cannot provide chart-based care without the chart. The FCP is what makes the chart possible.

NaProTechnology Medical Consultant (NFPMC)

A NaProTechnology Medical Consultant (NFPMC) is a physician (MD or DO) who has completed formal postgraduate training in NaProTechnology through an accredited program. Training routes include the fellowship at the Pope Paul VI Institute for the Study of Human Reproduction and the AAFCP Medical Consultant program. The credential is distinct from standard OBGYN or reproductive endocrinology training and requires specific coursework in Creighton Model charting interpretation, NaPro diagnostic protocols, and NaPro surgical technique.

Patients frequently search for a "NaPro doctor," "NaPro OBGYN," or "NaPro surgeon." These terms all describe the NFPMC role.

The NFPMC is distinct from an FCP (FertilityCare Practitioner). An FCP is a credentialed instructor of the Creighton Model Fertility Care System who teaches patients to observe and record their cycle. The NFPMC receives that chart data, runs the diagnostic workup, orders cycle-timed hormone panels, interprets results, prescribes medications, and performs surgical intervention when indicated. The physician and the practitioner work as a team. Neither role replaces the other.

The chart is not optional. An NFPMC practicing reproductive medicine without Creighton chart data is practicing without the diagnostic input that makes the NaPro approach function. The chart is the data source. The physician reads it.

See also: FertilityCare Practitioner (FCP), FertilityCare Practice, Creighton Model.

Transdermal Estrogen

Estrogen delivered through the skin via patch, gel, or cream, bypassing first-pass hepatic metabolism. Unlike oral estrogen, which passes through the liver before reaching systemic circulation, transdermal delivery provides steady-state estrogen levels with significantly lower impact on coagulation factors, C-reactive protein, and triglycerides. This pharmacokinetic difference is clinically important for women with thrombophilic risk factors or metabolic concerns.

In RRM practice, transdermal estrogen is used primarily for premature ovarian insufficiency and in selected perimenopausal management protocols. For women with POI, hormone replacement is not optional wellness support. It is medical necessity. Estrogen deficiency at age 28 or 34 carries cardiovascular, skeletal, and neurological consequences that accumulate silently without treatment. The goal is physiological replacement, not supraphysiologic dosing.

Transdermal delivery allows more precise titration than oral preparations and avoids the hepatic triglyceride stimulation associated with oral estrogen. Combined with progesterone support (typically micronized progesterone or a progestin), transdermal regimens can be tailored to the individual's hormonal profile, symptoms, and cycle remnants in women with partial ovarian function.

The distinction between transdermal estrogen as physiological replacement and suppressive medications is fundamental to RRM framing. Physiological replacement restores what the body cannot produce. Suppressive medications override what the body is producing. These are different pharmacological goals requiring different clinical conversations.

Follicle Stimulation / Ovulation Induction

The use of pharmacological agents to stimulate follicle development and ovulation in cycles where the natural process is inadequate or absent. In RRM and NaPro Medical protocols, ovulation induction uses oral agents, primarily clomiphene citrate or letrozole, timed to the follicular phase based on Creighton Model charting. The goal is to support the body's own ovulatory process, not to retrieve oocytes.

Letrozole (an aromatase inhibitor) is the preferred first-line agent for ovulation induction in many RRM protocols, particularly for PCOS and anovulatory infertility. The NEJM trial by Legro and colleagues demonstrated letrozole's superiority over clomiphene for live birth rates in PCOS.⁷⁶ Clomiphene remains in use where letrozole is not indicated or available, and in combination protocols.

Cycle monitoring during ovulation induction is standard in RRM practice. A follicle maturation study confirms follicle growth, guides the decision to add an HCG trigger, and identifies poor response early rather than after multiple failed cycles. Monitoring also prevents inadvertent multi-follicular development, which carries its own risks in natural conception protocols.

Ovulation induction in this context is fundamentally different from controlled ovarian hyperstimulation (COH) used in IVF protocols. COH intentionally stimulates multiple follicles for oocyte retrieval. RRM ovulation induction targets one well-developed follicle for in-body conception. The pharmacological agents may overlap. The clinical goals do not.

Part VIII: The Broader RRM Framework

NaProTECHNOLOGY vs. RRM

NaProTECHNOLOGY (NaPro) is the most established and studied approach within restorative reproductive medicine, developed by Dr. Thomas Hilgers at the Pope Paul VI Institute and based on the Creighton Model. RRM is a broader category describing approaches that share the restorative philosophy. NaPro practitioners may or may not identify their work under the RRM label. Other approaches that share this philosophy include: NeoFertility, Marquette Method-based medical management, FEMM-based care, and various symptothermal or sympto-hormonal approaches. All share the common framework of using biomarker data from cycle charting to optimize normal reproductive function.¹

IUI (Intrauterine Insemination)

Intrauterine insemination (IUI) is a procedure in which washed and concentrated sperm are deposited directly into the uterine cavity via a thin catheter at the time of ovulation, bypassing cervical mucus filtration. IUI is less invasive than IVF and does not involve external fertilization. Fertilization, if it occurs, happens in the fallopian tube. Indications include mild male factor infertility, cervical factor infertility, donor sperm use, and some cases of undiagnosed infertility. Per-cycle clinical pregnancy rates vary widely by age, sperm parameters, and the underlying cause of reduced fertility. IUI bypasses the cervical environment. It does not correct what made that bypass necessary. Within RRM, IUI is not a restorative therapy. NaProTECHNOLOGY and NeoFertility protocols do not employ IUI. Instead, clinicians time natural intercourse to cycle-identified fertile windows and correct the underlying causes of subfertility in one or both partners.

IVF (In Vitro Fertilization)

In vitro fertilization (IVF) is a form of assisted reproductive technology in which mature oocytes are retrieved from the ovaries via transvaginal aspiration after controlled ovarian hyperstimulation, fertilized externally in the laboratory (by conventional IVF or intracytoplasmic sperm injection, ICSI), cultured to cleavage or blastocyst stage, and transferred into the uterus as one or more embryos. IVF bypasses the reproductive process rather than restoring it. The underlying anatomical, hormonal, and immunologic problems that prevented conception remain uncorrected. Controlled hyperstimulation routinely produces more embryos than will be transferred. Those not transferred may be frozen, donated to other couples, donated for research, or destroyed. Each of those is a consequential decision, not a logistical one. Known risks include ovarian hyperstimulation syndrome (OHSS), multiple pregnancy when more than one embryo is transferred, elevated rates of preterm birth and low birthweight, and ongoing uncertainty about long-term offspring outcomes at the registry level. Per-cycle live-birth rates decline sharply with maternal age. Within RRM, IVF is a bypass technology. The question RRM asks is different: not how to work around a failing reproductive system, but what is causing it to fail, and whether that cause can be corrected. See IVF vs. RRM: Key Conceptual Distinctions for a side-by-side comparison.

IVF vs. RRM: Key Conceptual Distinctions

Patient-Centered Care

A guiding RRM value emphasizing patient understanding, informed consent, and active participation in health decisions. Fertility charting education gives patients direct insight into their own hormonal and physiological patterns. When treating for infertility or miscarriage, RRM clinicians treat the couple (both male and female) as a single unit.¹

Couple-Based Treatment

The RRM principle that when infertility or recurrent miscarriage is the concern, both partners receive evaluation and treatment as a unit. Male factor is the sole cause of infertility in approximately 20% of couples and a contributing factor in another 30 to 40%. Both partners are always assessed in RRM. This approach supports the relationship and reduces the emotional burden that often falls disproportionately on the female partner.³⁵

Minimally Invasive Surgery (MIS)

Surgical techniques (laparoscopic, hysteroscopic, robotic-assisted, or via mini-laparotomy) that minimize tissue trauma compared to open abdominal surgery, leading to faster recovery, less pain, fewer complications, and often superior fertility preservation. MIS is standard practice in RRM for all applicable procedures.¹

Adhesion Prevention

The active strategy employed in RRM/NaPro Surgery to minimize post-operative adhesion formation through meticulous hemostasis, careful tissue handling, thorough peritoneal irrigation, and the strategic use of anti-adhesion barriers (Gore-Tex membrane). One published NaPro series documented a mean adhesion score reduction from 33.3 to 6.0 over a decade with systematic barrier use.¹⁰

Antioxidant Therapy

The therapeutic use of antioxidant compounds to reduce oxidative stress in both male and female reproductive contexts. In males, antioxidants (vitamin C, E, CoQ10, zinc, selenium, L-carnitine, N-acetylcysteine) reduce sperm DNA fragmentation and improve sperm parameters. In females, antioxidants support oocyte quality, reduce endometriosis-related oxidative damage, and may support embryo development.²²¹⁹

Nutritional and Lifestyle Medicine

RRM incorporates assessment and optimization of nutritional status (vitamin D, folate, B12, iron, zinc, omega-3s) and lifestyle factors (sleep, stress, physical activity, body weight, environmental toxin exposure) as foundational elements of reproductive health restoration. Nutritional deficiencies and poor lifestyle factors are identified as contributing underlying factors, not peripheral concerns.³

Intracytoplasmic Sperm Injection (ICSI)

Intracytoplasmic sperm injection is a laboratory procedure in which a single sperm is selected and injected directly into an egg. It was developed in the early 1990s and became widespread as a solution for severe male factor infertility, where conventional IVF fertilization rates were poor.

ICSI has since expanded far beyond its original indication. It is now routinely used in IVF cycles even when sperm parameters are normal, often without clear clinical justification. When sperm quality is genuinely impaired, the underlying cause matters. ICSI bypasses the fertilization problem. It does not diagnose or treat the condition causing the impaired sperm.

From an RRM perspective, the first question is always: why is the sperm quality abnormal? Sperm DNA fragmentation, varicocele, hormonal imbalance, oxidative stress, and infection are all treatable causes that can be identified and addressed. Treating the root cause can improve sperm quality for natural conception. ICSI, by contrast, works around the problem while leaving it in place.

There are also recognized risks associated with ICSI that are not always discussed with couples before the procedure. The mechanical injection bypasses natural sperm selection mechanisms. The long-term safety data for offspring conceived via ICSI continues to be evaluated, and certain genetic risks, particularly in cases of severe male factor, may be transmissible to male offspring.⁶³

For couples where male factor is the primary barrier to natural conception, RRM evaluation of both partners is the starting point. Male evaluation, including semen analysis, hormonal panel, and sperm DNA fragmentation testing, identifies what is treatable. The goal is to restore fertility, not to engineer around it in a laboratory.

Ovarian Hyperstimulation Syndrome (OHSS)

Ovarian hyperstimulation syndrome is a complication of ovarian stimulation, most commonly occurring in the context of IVF. High doses of gonadotropins cause the ovaries to produce far more follicles than they would in a natural cycle. In susceptible women, this triggers a cascade of vascular permeability changes, fluid shifts, and electrolyte disturbances that can range from mild discomfort to a life-threatening medical emergency.

Mild OHSS is common. Severe OHSS requiring hospitalization is less frequent but not rare. Major professional societies have published guidance on classification and prevention, recognizing OHSS as an iatrogenic complication of ovarian stimulation protocols.⁶² Women with PCOS are at significantly higher risk because their ovaries already contain a large number of antral follicles that respond aggressively to stimulation.

OHSS does not occur in restorative reproductive medicine protocols. RRM uses low-dose, cycle-timed hormonal support to assist the body's own follicle development. Medications are used at physiologic doses to correct documented deficiencies, not to override the ovarian cycle with pharmacologic superstimulation. The risk of OHSS is specific to the ovarian stimulation paradigm, not to hormonal medicine broadly.

For women with PCOS who are offered IVF, OHSS risk should be part of an honest informed consent discussion. There are risk-reduction strategies within IVF protocols. But the more fundamental question is whether stimulation for IVF is the right starting point when the underlying cause of anovulation has not been evaluated or treated. Many women with PCOS can achieve natural conception with appropriate cycle support once the hormonal and metabolic contributors are identified.

OHSS is one of several reasons why RRM clinicians evaluate PCOS and anovulatory cycles with a restorative approach first. The goal is to support the cycle the patient has, not to replace it with an artificially stimulated one that carries its own risks.

Assisted Reproductive Technology (ART)

Assisted Reproductive Technology (ART) is the umbrella term for medical procedures that involve handling eggs, sperm, or embryos outside the body to achieve pregnancy. This includes in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), donor egg and donor sperm cycles, embryo transfer, and gestational surrogacy. Insurance documents, fertility clinic literature, and public health data all use ART as the standard classification.

ART procedures are bypass technologies. They work around reproductive barriers without investigating or treating the underlying cause. A woman with undiagnosed endometriosis who undergoes IVF still has endometriosis. A couple with undiagnosed male factor who pursues IUI still has an undiagnosed male factor. The conception method changes. The underlying condition does not.

RRM is not ART. The two approaches reflect opposite premises. ART proceeds from the assumption that the body cannot succeed and builds technology around that assumption. RRM asks why the body has not succeeded, then treats the answer. These are different questions, not competing techniques.

ART live-birth rates vary substantially by maternal age, diagnosis, and clinic. Per CDC and HFEA annual reporting, national averages for fresh non-donor IVF cycles decline sharply after age 35. Patients deserve accurate, age-stratified outcome data before consenting to any ART procedure.

See also: IVF, IUI, ICSI, IVF vs. RRM.

Oral Contraceptive (OC)

Oral contraceptives (OCs) are hormone-based medications taken by mouth to prevent pregnancy. Combined oral contraceptives (COCs) contain synthetic estrogen and progestin. Progestin-only pills contain progestin alone. Both work primarily by suppressing pituitary gonadotropin release, preventing ovulation. The menstrual cycle is not regulated by the pill; it is suppressed and replaced by a withdrawal bleed timed to the pill-free interval.

OCs are prescribed for contraception and for non-contraceptive indications: painful periods, PCOS symptom management, endometriosis-related pain, and acne. In each application, the mechanism is the same: cycle suppression. Symptoms may diminish while the medication is taken. The underlying condition does not change.

When a patient stops an OC prescribed for endometriosis pain, the disease remains, at whatever stage it reached during suppression. When a patient stops an OC prescribed for PCOS, the androgen excess and anovulation return. The suppression was not treatment. RRM clinicians use the term "suppressive medications" precisely because it names what these drugs do.

Documented effects associated with long-term OC use include changes in bone mineral density, cardiovascular risk markers, and mood. The strength of the evidence varies by outcome, and these risks are rarely discussed in standard prescribing conversations. Patients using OCs for years deserve that information.⁷¹

See also: Endometriosis, PCOS.

Intrauterine Device (IUD)

An intrauterine device (IUD) is a small, T-shaped device inserted into the uterine cavity for contraception. Two primary types are in clinical use.

The copper IUD works without hormones. Copper ions impair sperm motility and reduce fertilization. At higher concentrations, copper may also affect implantation if fertilization occurs, though the primary mechanism operates before fertilization.

The hormonal IUD releases levonorgestrel, a synthetic progestin, locally into the uterine cavity. It thickens cervical mucus, thins the endometrial lining, and may suppress ovulation in some users, particularly in the first year. Its primary mechanisms are cervical and endometrial. Whether post-fertilization effects occur remains a matter of scientific debate and is directly relevant to informed consent for couples who consider fertilization the beginning of a new life.⁷²

Side effects: the copper IUD frequently causes heavier menstrual bleeding and increased cramping. The hormonal IUD frequently causes irregular bleeding or amenorrhea. Amenorrhea eliminates menstrual cycle data as a diagnostic source. Both types carry a small risk of expulsion, uterine perforation at insertion, and infection during the insertion procedure.

RRM does not prescribe or recommend IUDs. Understanding how they work is part of informed care.

See also: Endometriosis, Recurrent Pregnancy Loss (RPL).

Hormone Replacement Therapy (HRT)

Hormone replacement therapy (HRT) refers to exogenous administration of estrogen, progesterone, or both, to supplement or replace hormonal production the body is no longer sustaining at adequate levels. Testosterone may also be included. HRT is used primarily for menopausal symptoms and for premature ovarian insufficiency (POI), a condition in which ovarian function declines before age 40.

RRM draws a clear distinction between two uses of exogenous hormones. The first: replacing what the body genuinely cannot produce. A 32-year-old with POI who has no functional ovarian estrogen production needs physiological replacement. That is restorative medicine. Without it, she faces accelerated bone loss, cardiovascular risk, and neurological effects. The second use: administering hormones to suppress or override normal reproductive function. RRM does not operate in the second category.

When HRT is medically indicated, RRM clinicians generally favor bioidentical hormone formulations. Bioidentical hormones are structurally identical to the hormones the body produces. Synthetic formulations are not. The evidence comparing bioidentical and synthetic preparations continues to develop, and the difference matters for receptor binding, metabolism, and long-term safety profile.

Patients with POI benefit from early, thorough evaluation before beginning HRT, including discussion of fertility implications. Evidence-based guidelines recommend HRT in POI until at least the average age of natural menopause, given the documented risks of untreated estrogen deficiency.⁷³

See also: Premature Ovarian Insufficiency (POI), Diminished Ovarian Reserve (DOR).

Abbreviations and Quick Reference